var docs;if (!docs) docs =[]; docs["113"]={"11303":"<p><b>Title</b> Pneumococcal Conjugate Vaccine (13-Valent) / Pneumococcal Polysaccharide Vaccine (23-Valent)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Indication</b>: The recommended interval between Pneumococcal Conjugate Vaccine (13-Valent) (PCV13) and Pneumococcal Polysaccharide Vaccine (23-Valent) (PPSV23) differs by the order in which the two vaccines are administered, patient age and risk group.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Pneumococcal Polysaccharide Vaccine (23-Valent) may diminish the therapeutic effect of Pneumococcal Conjugate Vaccine (13-Valent). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> It is recommended to administer PCV13 prior to administration of PPSV23. Separate the doses of PCV13 and PPSV23 in immunocompetent persons with underlying chronic conditions (eg, chronic heart disease, chronic lung disease, diabetes mellitus, alcoholism, chronic liver disease, cirrhosis, cigarette smoking) as follows: ages 24 months to 71 months (8 weeks at minimum), ages 65 years or greater (1 year at minimum). Separate the doses of PCV13 and PPSV23 in persons with immunocompromising conditions, functional or anatomic asplenia, cerebrospinal fluid (CSF) leaks, or cochlear implants as follows: ages 24 months or greater (8 weeks at minimum). <br><br>If PPSV23 is inadvertently administered before PCV13, separate the doses in immunocompetent persons with underlying chronic conditions as follows: ages 24 months to 71 months (8 weeks at minimum), ages 65 years or greater (1 year at minimum). Separate the vaccines in persons with immunocompromising conditions, functional or anatomic asplenia, CSF leaks, or cochlear implants as follows: ages 24 months to 18 years (8 weeks at minimum), ages 19 years or greater (1 year at minimum).<br><br>Regardless of vaccine sequence, separate the vaccines by 1 year at minimum in persons age 65 years or greater with no underlying condition. The vaccine series is not recommended in persons with no underlying conditions who are younger than 65 years or in immunocompetent persons 6 to 64 years of age with underlying chronic conditions.</p> \n<p><b>Discussion</b> Several studies have demonstrated an improved immune response against serotypes common to both the pneumococcal conjugate vaccine (13 Valent) (PCV13) and pneumococcal polysaccharide vaccine (23 Valent) (PPSV23) when the PCV13 vaccine was administered first.<sup>1,2,3,4</sup> <br><br>Studies have also shown a better antibody response when PCV13 and PPSV23 are administered at intervals greater than 1 year.<sup>1,2,5</sup> Further, vaccine intervals shorter than 8 weeks are not recommended due to the potential for increased local injection-site reactions compared with longer intervals.<sup>1,6</sup> <br><br>The Advisory Committee on Immunization Practices, a subcommittee of the Centers for Disease Control and Prevention (CDC), currently recommends that a dose of PCV13 be followed by a dose of PPSV23 in all adults aged 65 years or greater who have not previously received pneumococcal vaccine and in persons aged 2 years or greater who are at high risk for pneumococcal disease because of underlying medical conditions.<sup>1</sup> There are no available studies evaluating the efficacy of the vaccines administered in series; therefore, current recommendations are based on the best available evidence from immunogenicity studies.<br><br>The mechanism for the improved immune response seen with the PCV-PPSV23 sequence and longer dosing interval between vaccines is not fully understood, but may involve improved immunological memory when conjugated vaccines are followed by free polysaccharide vaccines.<sup>2,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kobayashi M, Bennett NM, Gierke R, et al. Intervals between PCV13 and PPSV23 Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP) [published correction appears in <i>MMWR Morb Mortal Wkly Rep</i>. 2015;64(34)]. <i>MMWR Morb Mortal Wkly Rep</i>. 2015;64(34):944-947. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26334788\">[PubMed 26334788]</a></p>\n<p>2. Greenberg RN, Gurtman A, Frenck RW, et al. Sequential administration of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults 60-64 years of age. <i>Vaccine</i>. 2014;32(20):2364-2374. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24606865\">[PubMed 24606865]</a></p>\n<p>3. Musher DM, Rueda AM, Nahm MH, et al. Initial and subsequent response to pneumococcal polysaccharide and protein-conjugate vaccines administered sequentially to adults who have recovered from pneumococcal pneumonia. <i>J Infect Dis</i>. 2008;198(7):1019-1027. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18710324\">[PubMed 18710324]</a></p>\n<p>4. Blum MD, Dagan R, Mendelman PM, et al. A comparison of multiple regimens of pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers. <i>Vaccine</i>. 2000;18(22):2359-2367. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10738092\">[PubMed 10738092]</a></p>\n<p>5. Jackson LA, Gurtman A, van Cleeff M, et al. Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and older. <i>Vaccine</i>. 2013;31(35):3594-3602. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23688525\">[PubMed 23688525]</a></p>\n<p>6. Miernyk KM, Butler JC, Bulkow LR, et al. Immunogenicity and reactogenicity of pneumococcal polysaccharide and conjugate vaccines in alaska native adults 55-70 years of age. <i>Clin Infect Dis</i>. 2009;49(2):241-248. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19522655\">[PubMed 19522655]</a></p>\n<p>7. de Roux A, Schmole-Thoma B, Siber GR, et al. Comparison of pneumococcal conjugate polysaccharide and free polysaccharide vaccines in elderly adults: conjugate vaccine elicits improved antibacterial immune responses and immunological memory [published correction appears in <i>Clin Infect Dis</i>. 2008;46(9):1488]. <i>Clin Infect Dis</i>. 2008;46(7):1015-1023. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18444818\">[PubMed 18444818]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11304":"<p><b>Title</b> Mivacurium / Cyclophosphamide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cyclophosphamide may increase the serum concentration of Mivacurium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for enhanced/prolonged effects of mivacurium if combined with cyclophosphamide or if cyclophosphamide has been used in the previous 10 days. Consider reducing the mivacurium dose or using neuromuscular-blocking agents other than mivacurium or succinylcholine.</p> \n<p><b>Discussion</b> Prolonged apnea and other symptoms of respiratory insufficiency have been reported in patients receiving succinylcholine following cyclophosphamide administration.<sup>1,2,3,4</sup> Although the combination of cyclophosphamide and mivacurium has not been evaluated, cyclophosphamide can cause prolonged inhibition of pseudocholinesterase, a serum enzyme that metabolizes both succinylcholine and mivacurium. <br><br>US prescribing information for cyclophosphamide states because cyclophosphamide causes a marked and persistent inhibition of pseudocholinesterase activity, prolonged apnea and neuromuscular blockade may occur up to 10 days after cyclophosphamide administration with concurrent use of neuromuscular-blocking drugs that rely on pseudocholinesterase for elimination (eg, succinylcholine, mivacurium).<sup>5</sup> Based on one published case report, this interaction may be managed in some patients with succinylcholine dose reduction and close monitoring,<sup>6</sup> although general recommendations are not currently available.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Walker IR, Zapf PW, Mackay IR. Cyclophosphamide, cholinesterase, and anaesthesia. <i>Aust NZ J Med</i>. 1972;2(3):247-251. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4508246\">[PubMed 4508246]</a></p>\n<p>2. Zsigmond EK, Robins G. The effect of a series of anti-cancer drugs on plasma cholinesterase activity. <i>Can Anaesth Soc J</i>. 1972;19(1):75-82. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4257896\">[PubMed 4257896]</a></p>\n<p>3. Mone JG, Mathie WE. Qualitative defects of pseudocholinesterase activity. <i>Anaesthesia</i>. 1967;22(1):55-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4959505\">[PubMed 4959505]</a></p>\n<p>4. Norris JC. Prolonged succinylcholine apnoea resulting from acquired deficiency of plasma cholinesterase. <i>Anaesthesia</i>. 2003;58(11):1137. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14616624\">[PubMed 14616624]</a></p>\n<p>5. Cytoxan (cyclophosphamide) [prescribing information]. Deerfield, IL: Baxter Healthcare Corporation; April 2012.</p>\n<p>6. Dillman JB. Safe use of succinylcholine during repeated anesthetics in a patient treated with cyclophosphamide. <i>Anesth Analg</i>. 1987;66(4):351-353. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3565800\">[PubMed 3565800]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11305":"<p><b>Title</b> Mivacurium / Echothiophate Iodide</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Echothiophate Iodide may increase the serum concentration of Mivacurium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for enhanced/prolonged effects of mivacurium if combined with echothiopate iodide. Consider reducing the mivacurium dose or using neuromuscular-blocking agents other than mivacurium or succinylcholine.</p> \n<p><b>Discussion</b> Case reports of prolonged apnea from succinylcholine in patients receiving echothiophate iodide eye drops have been published.<sup>1,2,3</sup> Although the combination of echothiopate iodide and mivacurium has not been evaluated, echothiophate iodide eye drops, even in doses as low as two drops of a 0.06% solution in each eye 3 times/week, can reduce pseudocholinesterase activity as much as 50%.<sup>4</sup> Pseudocholinesterase is the serum enzyme that metabolizes both succinylcholine and mivacurium. <br><br>The likely mechanism of this interaction is echothiophate inhibition of pseudocholinesterase-mediated succinylcholine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gesztes T. Prolonged apnoea after suxamethonium injection associated with eye drops containing an anticholinesterase agent. <i>Br J Anaesth</i>. 1966;38(5):408-409. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5939140\">[PubMed 5939140]</a></p>\n<p>2. Pantuck EJ. Ecothiopate iodide eye drops and prolonged response to suxamethonium. <i>Br J Anaesth</i>. 1966;38(5):406-407. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5939139\">[PubMed 5939139]</a></p>\n<p>3. Mone JG, Mathie WE. Qualitative defects of pseudocholinesterase activity. <i>Anaesthesia</i>. 1967;22(1):55-68. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4959505\">[PubMed 4959505]</a></p>\n<p>4. Eilderton TE, Farmati O, Zsigmond EK. Reduction in plasma cholinesterase levels after prolonged administration of echothiophate iodide eyedrops. <i>Can Anaesth Soc J</i>. 1968;15(3):291-296. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5658433\">[PubMed 5658433]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11306":"<p><b>Title</b> Mivacurium / Phenelzine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Phenelzine may increase the serum concentration of Mivacurium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased therapeutic effects of mivacurium (eg, prolonged apnea) if phenelzine is being taken/or has recently been discontinued. Consider a lower initial dose of mivacurium in patients who are receiving or have recently received (within last 2 weeks) phenelzine.</p> \n<p><b>Discussion</b> One case report describes a phenelzine-treated patient who developed prolonged apnea in response to succinylcholine administration.<sup>1</sup> The patient was discovered to have decreased plasma pseudocholinesterase concentrations at the time of her apnea, but her pseudocholinesterase concentrations returned to normal after phenelzine discontinuation.<sup>1</sup> Three additional phenelzine-treated patients were also noted to have reduced serum pseudocholinesterase concentrations.<sup>1</sup> Although the combination of phenelzine and mivacurium has not been evaluated, pseudocholinesterase is a serum enzyme that metabolizes both mivacurium and succinylcholine. <br><br>The mechanism of this potential interaction is likely due to phenelzine-mediated inhibition of pseudocholinesterase, and enzyme responsible for succinylcholine (and mivacurium) metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bodley PO, Halwax K, Potts L. Low serum pseudocholinesterase levels complicating treatment with phenelzine. <i>Br Med J</i>. 1969;3(5669):510-512. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=5801348\">[PubMed 5801348]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11307":"<p><b>Title</b> Mivacurium / Sertraline</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sertraline may increase the serum concentration of Mivacurium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for enhanced/prolonged effects of mivacurium (eg, prolonged apnea) if combined with sertraline. Consider a lower initial dose of mivacurium in patients who are receiving sertraline.</p> \n<p><b>Discussion</b> One case report describes a 47-year-old man taking sertraline for 3 years who experienced prolonged apnea after mivacurium administration during a laparoscopic cholecystectomy and was found to have an extremely low pseudocholinesterase plasma level (788 units/L).<sup>1</sup> The low pseudocholinesterase level was unexpected, as the patient had received succinylcholine (another neuromuscular-blocking agent metabolized by pseudocholinesterase) during 2 previous operations (28 and 19 years previously) without experiencing prolonged apnea. Although he was never rechallenged with mivacurium, after discontinuation of sertraline, his pseudocholinesterase plasma concentration returned to normal (2,762 units/L).<sup>1</sup><br><br>The suspected mechanism of this interaction is sertraline-mediated inhibition of pseudocholinesterase,<sup>2,3</sup> an enzyme responsible for mivacurium metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zencirci B. Sertraline-induced pseudocholinesterase enzyme deficiency. <i>Int J Gen Med</i>. 2010;3:375-378. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21189834\">[PubMed 21189834]</a></p>\n<p>2. Muller TC, Rocha JB, Morsch VM, Neis RT, Schetinger MR. Antidepressants inhibit human acetylcholinesterase and butyrylcholinesterase activity.<i>Biochim Biophys Acta</i>. 2002;1587(1):92-98. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12009429\">[PubMed 12009429]</a></p>\n<p>3. Ahmed M, Batista J, Rocha T, et al. Comparative study of the inhibitory effect of antidepressants on cholinesterase activity in Bungarus sindanus (krait) venom, human serum, and rat striatum. <i>J Enzyme Inhib Med Chem</i>. 2008;23(6):912-917. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18608756\">[PubMed 18608756]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11308":"<p><b>Title</b> Succinylcholine / Sertraline</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Sertraline may increase the serum concentration of Succinylcholine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for enhanced/prolonged effects of succinylcholine (eg, prolonged apnea) if combined with sertraline. Consider a lower initial dose of succinylcholine in patients who are receiving sertraline.</p> \n<p><b>Discussion</b> One case report describes a 47-year-old man taking sertraline for 3 years who experienced prolonged apnea after mivacurium administration during a laparoscopic cholecystectomy and was found to have an extremely low pseudocholinesterase plasma level (788 units/L).<sup>1</sup> The low pseudocholinesterase level was unexpected, as the patient had received succinylcholine (another neuromuscular-blocking agent metabolized by pseudocholinesterase) during 2 previous operations (28 and 19 years previously) without experiencing prolonged apnea. Although he was never rechallenged with mivacurium, after discontinuation of sertraline, his pseudocholinesterase plasma concentration returned to normal (2,762 units/L).<sup>1</sup><br><br>The suspected mechanism of this interaction is sertraline-mediated inhibition of pseudocholinesterase,<sup>2,3</sup> an enzyme responsible for mivacurium (and succinylcholine) metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zencirci B. Sertraline-induced pseudocholinesterase enzyme deficiency. <i>Int J Gen Med</i>. 2010;3:375-378. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21189834\">[PubMed 21189834]</a></p>\n<p>2. Muller TC, Rocha JB, Morsch VM, Neis RT, Schetinger MR. Antidepressants inhibit human acetylcholinesterase and butyrylcholinesterase activity. <i>Biochim Biophys Acta</i>. 2002;1587(1):92-98. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12009429\">[PubMed 12009429]</a></p>\n<p>3. Ahmed M, Batista J, Rocha T, et al. Comparative study of the inhibitory effect of antidepressants on cholinesterase activity in Bungarus sindanus (krait) venom, human serum, and rat striatum. <i>J Enzyme Inhib Med Chem</i>. 2008;23(6):912-917. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18608756\">[PubMed 18608756]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11309":"<p><b>Title</b> Raltegravir / Calcium Carbonate</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Calcium Carbonate may decrease the serum concentration of Raltegravir. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of once-daily raltegravir (Isentress HD) with calcium carbonate antacid is not recommended. Use of other raltegravir products with calcium carbonate do not require any dose change.</p> \n<p><b>Discussion</b> In a clinical study summarized in raltegravir U.S. prescribing information, simultaneous coadministration of calcium carbonate (3 g single dose) decreased raltegravir (400 mg twice daily) AUC and minimum serum concentration (Cmin) by 55% and 32%, respectively.<sup>1</sup> When calcium carbonate (3 g single dose) was administered with raltegravir 1200 mg once daily, the raltegravir AUC and Cmin were reduced by an average of 72% and 48%, respectively.<sup>1</sup> Concurrent use of once-daily raltegravir (Isentress HD) with calcium carbonate antacid is not recommended.<sup>1</sup> Use of other raltegravir products with calcium carbonate do not require any dose change.<br><br>The suspected primary mechanism of these interactions is raltegravir chelation to divalent cations in the gastrointestinal tract, resulting in formation of complexes with reduced solubility.<sup>1,2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Isentress (raltegravir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; May 2017.</p>\n<p>2. Moss DM, Siccardi M, Murphy M, et al. Divalent metals and pH alter raltegravir disposition in vitro. <i>Antimicrob Agents Chemother</i>. 2012;56(6):3020-3026. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22450971\">[PubMed 22450971]</a></p>\n<p>3. Bacchi A, Carcelli M, Compari C, et al. Investigating the role of metal chelation in HIV-1 integrase strand transfer inhibitors. <i>J Med Chem</i>. 2011;54(24):8407-8420. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22066494\">[PubMed 22066494]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11310":"<p><b>Title</b> Raltegravir / Etravirine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Brand Name</b>: Concurrent use of etravirine with once-daily raltegravir (Isentress HD) is not recommended.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Etravirine may decrease the serum concentration of Raltegravir. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Concurrent use of etravirine with once-daily raltegravir (Isentress HD) is not recommended. Concurrent use of other raltegravir products with etravirine does not require any dose change.</p> \n<p><b>Discussion</b> In a clinical study summarized in raltegravir U.S. prescribing information, simultaneous coadministration of etravirine (200 mg twice daily) and raltegravir (400 mg twice daily) was associated with a an average 10% and 34% decrease in the raltegravir AUC and minimum serum concentration (Cmin).<sup>1</sup> Concurrent use of once-daily raltegravir (Isentress HD) with etravirine is not recommended, but use of other raltegravir products with etravirine does not require any dose change.<sup>1</sup><br><br>The suspected primary mechanism of this interaction is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Isentress (raltegravir) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co., Inc.; May 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11311":"<p><b>Title</b> Succinylcholine / Estrogen Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Estrogen Derivatives may increase the serum concentration of Succinylcholine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for enhanced/prolonged effects of succinylcholine (eg, prolonged apnea) if combined with estrogen derivatives. Consider a lower initial dose of succinylcholine in patients who are receiving estrogens.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n</div> \n<p><b>Discussion</b> One case report describes a 32-year-old transgender female taking estradiol (oral and transdermal) who experienced prolonged apnea after receiving succinylcholine during electroconvulsive therapy (ECT).<sup>1</sup> The patient was discovered to have reduced plasma pseudocholinesterase activity, which was notable because she had tolerated 2 previous surgeries and anesthesia without experiencing any episodes of prolonged apnea prior to estradiol therapy. Subsequent ECT treatments were tolerated without prolonged apnea by use of a reduced succinylcholine dose.<sup>1</sup> Another case report describes a 78-year-old man taking diethylstilbestrol (1 mg three times daily) for 2 months who experienced prolonged apnea following the administration of succinylcholine (140 mg total).<sup>2</sup> He had reduced plasma pseudocholinesterase activity despite tolerating succinylcholine therapy with 2 previous surgeries.<sup>2</sup> Three months after discontinuation of diethylstilbestrol, the plasma pseudocholinesterase activity had increased, but was still not within normal limits.<sup>2</sup> Other studies have found that plasma pseudocholinesterase activity is reduced in women taking estrogen-containing oral contraceptives compared with women not taking contraceptives.<sup>3,4</sup><br><br>In contrast, one study found that while plasma pseudocholinesterase activity was reduced in women taking oral contraceptives, their response to succinylcholine was not prolonged and the changes in pseudocholinesterase activity were not clinically relevant.<sup>5</sup><br><br>Product labeling for both succinylcholine and mivacurium (neuromuscular-blocking drugs metabolized by plasma pseudocholinesterase) both state that neuromuscular-blocking effects may be enhanced by drugs that reduce plasma cholinesterase activity, such as estrogens.<sup>6,7</sup><br><br>The suspected mechanism of this potential interaction is due to estrogen-mediated inhibition of plasma pseudocholinesterase, the enzyme responsible for succinylcholine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tran BK, O'Donnell SE, Balla A, Adams DC, Grondin LS, Tsai MH. Electroconvulsive therapy considerations for transgendered patients. <i>J ECT</i>. 2017;33(2):e14-e16. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28009618\">[PubMed 28009618]</a></p>\n<p>2. Archer TL, Janowsky EC. Plasma pseudocholinesterase deficiency associated with diethylstilbestrol therapy. <i>Anesth Analg</i>. 1978;57(6):726-732. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=569997\">[PubMed 569997]</a></p>\n<p>3. Robertson GS. Serum protein and cholinesterase changes in association with contraceptive pills. <i>Lancet</i>. 1967;1(7484):232-235. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4163143\">[PubMed 4163143]</a></p>\n<p>4. Sidell FR, Kaminskis A. Influence of age, sex, and oral contraceptives on human blood cholinesterase activity. <i>Clin Chem</i>. 1975;21(10):1393-1395. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1157304\">[PubMed 1157304]</a></p>\n<p>5. Leighton BL, Cheek TG, Gross JB, et al. Succinylcholine pharmacodynamics in peripartum patients. <i>Anesthesiology</i>. 1986;64(2):202-205. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3946807\">[PubMed 3946807]</a></p>\n<p>6. Mivacron (mivacurium) [prescribing information]. North Chicago, IL: AbbVie Inc; January 2015.</p>\n<p>7. Anectine (succinylcholine) [prescribing information]. Princeton, NJ: Sandoz Inc; November 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11312":"<p><b>Title</b> Mivacurium / Estrogen Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Estrogen Derivatives may increase the serum concentration of Mivacurium. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for enhanced/prolonged effects of mivacurium (eg, prolonged apnea) if combined with estrogen derivatives. Consider a lower initial dose of mivacurium in patients who are receiving estrogens.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n</div> \n<p><b>Discussion</b> One case report describes a 32-year-old transgender female taking estradiol (oral and transdermal) who experienced prolonged apnea after receiving succinylcholine during electroconvulsive therapy (ECT).<sup>1</sup> The patient was discovered to have reduced plasma pseudocholinesterase activity, which was notable because she had tolerated 2 previous surgeries and anesthesia without experiencing any episodes of prolonged apnea prior to estradiol therapy. Subsequent ECT treatments were tolerated without prolonged apnea by use of a reduced succinylcholine dose.<sup>1</sup> Another case report describes a 78-year-old man taking diethylstilbestrol (1 mg three times daily) for 2 months who experienced prolonged apnea following the administration of succinylcholine (140 mg total).<sup>2</sup> He had reduced plasma pseudocholinesterase activity despite tolerating succinylcholine therapy with 2 previous surgeries.<sup>2</sup> Three months after discontinuation of diethylstilbestrol, the plasma pseudocholinesterase activity had increased, but was still not within normal limits.<sup>2</sup> Other studies have found that plasma pseudocholinesterase activity is reduced in women taking estrogen-containing oral contraceptives compared with women not taking contraceptives.<sup>3,4</sup><br><br>In contrast, one study found that while plasma pseudocholinesterase activity was reduced in women taking oral contraceptives, their response to succinylcholine was not prolonged and the changes in pseudocholinesterase activity were not clinically relevant.<sup>5</sup><br><br>Product labeling for both succinylcholine and mivacurium (neuromuscular-blocking drugs metabolized by plasma pseudocholinesterase) both state that neuromuscular-blocking effects may be enhanced by drugs that reduce plasma cholinesterase activity, such as estrogens.<sup>6,7</sup><br><br>The suspected mechanism of this potential interaction is due to estrogen-mediated inhibition of plasma pseudocholinesterase, the enzyme responsible for succinylcholine (and mivacurium) metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Tran BK, O'Donnell SE, Balla A, Adams DC, Grondin LS, Tsai MH. Electroconvulsive therapy considerations for transgendered patients. <i>J ECT</i>. 2017;33(2):e14-e16. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28009618\">[PubMed 28009618]</a></p>\n<p>2. Archer TL, Janowsky EC. Plasma pseudocholinesterase deficiency associated with diethylstilbestrol therapy. <i>Anesth Analg</i>. 1978;57(6):726-732. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=569997\">[PubMed 569997]</a></p>\n<p>3. Robertson GS. Serum protein and cholinesterase changes in association with contraceptive pills. <i>Lancet</i>. 1967;1(7484):232-235. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4163143\">[PubMed 4163143]</a></p>\n<p>4. Sidell FR, Kaminskis A. Influence of age, sex, and oral contraceptives on human blood cholinesterase activity. <i>Clin Chem</i>. 1975;21(10):1393-1395. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1157304\">[PubMed 1157304]</a></p>\n<p>5. Leighton BL, Cheek TG, Gross JB, et al. Succinylcholine pharmacodynamics in peripartum patients. <i>Anesthesiology</i>. 1986;64(2):202-205. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3946807\">[PubMed 3946807]</a></p>\n<p>6. Mivacron (mivacurium) [prescribing information]. North Chicago, IL: AbbVie Inc; January 2015.</p>\n<p>7. Anectine (succinylcholine) [prescribing information]. Princeton, NJ: Sandoz Inc; November 2010.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11313":"<p><b>Title</b> Cetirizine (Systemic) / Ombitasvir, Paritaprevir, and Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, and Ritonavir may increase the serum concentration of Cetirizine (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required. The clinical relevance of the possible increase in cetirizine concentrations/exposure with ritonavir and/or ritonavir-containing products is uncertain.</p> \n<p><b>Discussion</b> In an open-label crossover study, 17 subjects received cetirizine alone (10mg/day x 4 days), ritonavir alone (300mg twice daily titrated to 600mg twice daily for at least 7 days), and cetirizine plus ritonavir (10mg/day and 600mg twice daily, respectively, x 4 days).<sup>1</sup> Compared to cetirizine alone, when combined with ritonavir cetirizine AUC increased by 42%, clearance decreased by 29%, and elimination half-life increased by 53%. Despite these significant changes, none of the 16 subjects completing the study (1 dropped out after the cetirizine alone arm) reported any adverse effects while receiving the combination. Longer term clinical consequences of such increased exposure to cetirizine are unclear, but considering the safety profile of cetirizine (particularly in other populations where concentrations/AUC are increased), serious adverse effects would not be expected.<br><br>The mechanism of this apparent interaction is unclear. Ritonavir is a potent inhibitor of drug metabolizing enzymes, such as CYP3A4, but cetirizine is only minimally metabolized<sup>2</sup> making inhibition of metabolism unlikely to fully explain the observed changes. Ritonavir is also an inhibitor of certain drug transporters, such as the efflux transporter p-glycoprotein, and considering that cetirizine is a p-glycoprotein substrate,<sup>3</sup> it is possible that ritonavir inhibition of cetirizine tubular secretion could explain this apparent interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Peytavin G, Gautran C, Otoul C, et al. Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. <i>Eur J Clin Pharmacol</i>. 2005;61(4):267-273. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15889300\">[PubMed 15889300]</a> </p>\n<p>2. Wood SG, John BA, Chasseaud LF, Yeh J, Chung M. The metabolism and pharmacokinetics of 14C-cetirizine in humans. <i>Ann Allergy</i>. 1987;59(6)(pt 2):31-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2892447\">[PubMed 2892447]</a> </p>\n<p>3. Polli JW, Baughman TM, Humphreys JE, et al. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. <i>J Pharm Sci</i>. 2003;92(10):2082-2089. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14502547\">[PubMed 14502547]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11314":"<p><b>Title</b> Cetirizine (Systemic) / Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir may increase the serum concentration of Cetirizine (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required. The clinical relevance of the possible increase in cetirizine concentrations/exposure with ritonavir and/or ritonavir-containing products is uncertain.</p> \n<p><b>Discussion</b> In an open-label crossover study, 17 subjects received cetirizine alone (10mg/day x 4 days), ritonavir alone (300mg twice daily titrated to 600mg twice daily for at least 7 days), and cetirizine plus ritonavir (10mg/day and 600mg twice daily, respectively, x 4 days).<sup>1</sup> Compared to cetirizine alone, when combined with ritonavir cetirizine AUC increased by 42%, clearance decreased by 29%, and elimination half-life increased by 53%. Despite these significant changes, none of the 16 subjects completing the study (1 dropped out after the cetirizine alone arm) reported any adverse effects while receiving the combination. Longer term clinical consequences of such increased exposure to cetirizine are unclear, but considering the safety profile of cetirizine (particularly in other populations where concentrations/AUC are increased), serious adverse effects would not be expected.<br><br>The mechanism of this apparent interaction is unclear. Ritonavir is a potent inhibitor of drug metabolizing enzymes, such as CYP3A4, but cetirizine is only minimally metabolized<sup>2</sup> making inhibition of metabolism unlikely to fully explain the observed changes. Ritonavir is also an inhibitor of certain drug transporters, such as the efflux transporter p-glycoprotein, and considering that cetirizine is a p-glycoprotein substrate,<sup>3</sup> it is possible that ritonavir inhibition of cetirizine tubular secretion could explain this apparent interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Peytavin G, Gautran C, Otoul C, et al. Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. <i>Eur J Clin Pharmacol</i>. 2005;61(4):267-273. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15889300\">[PubMed 15889300]</a> </p>\n<p>2. Wood SG, John BA, Chasseaud LF, Yeh J, Chung M. The metabolism and pharmacokinetics of 14C-cetirizine in humans. <i>Ann Allergy</i>. 1987;59(6)(pt 2):31-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2892447\">[PubMed 2892447]</a> </p>\n<p>3. Polli JW, Baughman TM, Humphreys JE, et al. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. <i>J Pharm Sci</i>. 2003;92(10):2082-2089. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14502547\">[PubMed 14502547]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11315":"<p><b>Title</b> Cetirizine (Systemic) / Ritonavir</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ritonavir may increase the serum concentration of Cetirizine (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required. The clinical relevance of the possible increase in cetirizine concentrations/exposure with ritonavir is uncertain.</p> \n<p><b>Discussion</b> In an open-label crossover study, 17 subjects received cetirizine alone (10mg/day x 4 days), ritonavir alone (300mg twice daily titrated to 600mg twice daily for at least 7 days), and cetirizine plus ritonavir (10mg/day and 600mg twice daily, respectively, x 4 days).<sup>1</sup> Compared to cetirizine alone, when combined with ritonavir cetirizine AUC increased by 42%, clearance decreased by 29%, and elimination half-life increased by 53%. Despite these significant changes, none of the 16 subjects completing the study (1 dropped out after the cetirizine alone arm) reported any adverse effects while receiving the combination. Longer term clinical consequences of such increased exposure to cetirizine are unclear, but considering the safety profile of cetirizine (particularly in other populations where concentrations/AUC are increased), serious adverse effects would not be expected.<br><br>The mechanism of this apparent interaction is unclear. Ritonavir is a potent inhibitor of drug metabolizing enzymes, such as CYP3A4, but cetirizine is only minimally metabolized<sup>2</sup> making inhibition of metabolism unlikely to fully explain the observed changes. Ritonavir is also an inhibitor of certain drug transporters, such as the efflux transporter p-glycoprotein, and considering that cetirizine is a p-glycoprotein substrate,<sup>3</sup> it is possible that ritonavir inhibition of cetirizine tubular secretion could explain this apparent interaction.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Peytavin G, Gautran C, Otoul C, et al. Evaluation of pharmacokinetic interaction between cetirizine and ritonavir, an HIV-1 protease inhibitor, in healthy male volunteers. <i>Eur J Clin Pharmacol</i>. 2005;61(4):267-273. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15889300\">[PubMed 15889300]</a> </p>\n<p>2. Wood SG, John BA, Chasseaud LF, Yeh J, Chung M. The metabolism and pharmacokinetics of 14C-cetirizine in humans. <i>Ann Allergy</i>. 1987;59(6)(pt 2):31-34. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2892447\">[PubMed 2892447]</a> </p>\n<p>3. Polli JW, Baughman TM, Humphreys JE, et al. P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. <i>J Pharm Sci</i>. 2003;92(10):2082-2089. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=14502547\">[PubMed 14502547]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11316":"<p><b>Title</b> Pilsicainide / Cetirizine (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Pilsicainide may increase the serum concentration of Cetirizine (Systemic). Cetirizine (Systemic) may increase the serum concentration of Pilsicainide. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for pilsicainide toxicities (eg, QT prolongation, QRS widening, AV block, dizziness) if combined with cetirizine. Consider monitoring patients for signs of cetirizine toxicity (eg, drowsiness, headache). Dose reductions of both drugs or a change to alternate therapy may be needed.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 6 healthy volunteers, coadministration of cetirizine (20 mg single dose) and pilsicainide (50 mg single dose) increased the pilsicainide and cetirizine AUC 36% and 41%, respectively.<sup>1</sup> Renal clearance of pilsicainide decreased 41% and cetirizine renal clearance decreased 38%.<sup>1</sup> The same report describes a female patient with renal insufficiency taking pilsicainide (150 mg daily) who experienced faintness, hypotension, bradycardia, and QT interval prolongation 3 days after initiation of cetirizine (20 mg daily).<sup>1</sup> Her symptoms resolved and her ECG normalized with pilsicainide discontinuation.<sup>1</sup> Concentrations of both pilsicainide and cetirizine were markedly elevated during coadministration, and cetirizine levels returned to therapeutic concentrations after pilsicainide discontinuation.<sup>1</sup> <br><br>Pilsicainide product labeling states that increased concentrations of both drugs and associated adverse effects may occur with coadministration.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated, but an in vitro study suggests that cetirizine and pilsicainide may both be substrates and inhibitors of the renal transporters (MDR1 and/or OCT2) responsible for the active renal secretion of both agents.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tsuruoka S, Ioka T, Wakaumi M, Sakamoto K, Ookami H, Fujimura A. Severe arrhythmia as a result of the interaction of cetirizine and pilsicainide in a patient with renal insufficiency: first case presentation showing competition for excretion via renal multidrug resistance protein 1 and organic cation transporter 2. <i>Clin Pharmacol Ther</i>. 2006;79(4):389-396. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16580907\">[PubMed 16580907]</a></p>\n<p>2. Sunrythm (pilsicainide) [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200705941. Accessed September 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11317":"<p><b>Title</b> Pneumococcal Conjugate Vaccine (13-Valent) / Meningococcal (Groups A / C / Y and W-135) Diphtheria Conjugate Vaccine</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Comorbidity</b>: The recommended interval between pneumococcal conjugate vaccine (13-valent) (PCV13) and meningococcal (groups A / C / Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MenACYW-D) is specific to persons with anatomic asplenia (surgical removal or congenital absence of the spleen) or functional asplenia (as occurs in persons with sickle cell disease).</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Meningococcal (Groups A / C / Y and W-135) Diphtheria Conjugate Vaccine may diminish the therapeutic effect of Pneumococcal Conjugate Vaccine (13-Valent). <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Administer PCV13 at least 4 weeks prior to the administration of MenACYW-D vaccine in persons with anatomic asplenia or functional asplenia.</p> \n<p><b>Discussion</b> It is recommended to administer PCV13 at least 4 weeks prior to the administration of MenACYW-D vaccine in persons with anatomic asplenia or functional asplenia.<sup>1</sup><br><br>An immunogenicity study reported in the product label for MenACYW-D vaccine (Menactra brand) demonstrated a reduced antibody response for 3 of 7 serotypes of pneumococcus (subtypes 4, 6B, and 18C) when MenACYW-D vaccine and pneumococcal conjugate vaccine (7-valent) (an earlier pneumococcal vaccine) were administered simultaneously compared with separate administration.<sup>2</sup><br><br>Persons with anatomic asplenia or functional asplenia are at increased risk for infection by encapsulated bacteria, including <i>Streptococcus pneumoniae</i> (pneumococcus) and <i>Neisseria meningitidis</i> (meningococcus). Accordingly, the Advisory Committee on Immunization Practices (ACIP), a subcommittee of the Centers for Disease Control and Prevention (CDC), recommends immunization against these pathogens in patients with anatomic asplenia or functional asplenia.<sup>1</sup> Further, the ACIP states that the MenACYW-D vaccine should be administered at least 4 weeks following the final dose of PCV13 in all patients with anatomic asplenia or functional asplenia.<br><br>MenACYW-D vaccine and PCV13 contain diphtheria-toxoid conjugates. The mechanism for this interaction is likely due to reduced immunologic memory witnessed with the simultaneous administration of vaccines containing like conjugates.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. CDC. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. <i>MMWR Morb Mortal Wkly Rep</i>. 2011;60(40):1391-1392. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21993344\">[PubMed 21993344]</a></p>\n<p>2. Meningococcal (Groups A / C / Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MenACYW-D) (menactra) [prescribing information]. Swiftwater, PA: Sanofi Pasteur Inc; September 2016.</p>\n<p>3. Pobre K, Tashani M, Ridda I, et al. Carrier priming or suppression: understanding carrier priming enhancement of anti-polysaccharide antibody response to conjugate vaccines. <i>Vaccine</i>. 2014;32(13):1423-1430. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24492014\">[PubMed 24492014]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11318":"<p><b>Title</b> Vaccines (Live) / Vaccines (Live)</p> \n<p><span style=\"color: red; font-weight: bold\">Dependencies</span> </p>\n<ul>\n <li><p><b>Dosage Form</b>: This interaction is specific to injectable or nasally administered live vaccines and does not apply to live oral vaccines.</p></li>\n</ul>\n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Vaccines (Live) may diminish the therapeutic effect of other Vaccines (Live). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Two or more live injectable or nasally administered vaccines can be administered together on the same day. If they are not administered on the same day, then the administration should be separated by at least 28 days (ie, 4 weeks). <br><br>On the day a live injectable or intranasal vaccine will be administered, providers should ensure that no live injectable or intranasal vaccine was given in the previous 4 weeks.</p>\n<div>\n <p><b>Vaccines (Live) Interacting Members</b> BCG Vaccine (Immunization), Influenza Virus Vaccine (Live/Attenuated), Japanese Encephalitis Virus Vaccine (Live/Attenuated), Measles, Mumps, and Rubella Virus Vaccine, Measles, Mumps, Rubella, and Varicella Virus Vaccine, Poliovirus Vaccine (Live/Bivalent/Oral), Poliovirus Vaccine (Live/Trivalent/Oral), Smallpox Vaccine Live, Typhoid Vaccine, Varicella Virus Vaccine, Yellow Fever Vaccine, Zoster Vaccine (Live/Attenuated)<br><b>Exceptions</b> Adenovirus (Types 4, 7) Vaccine, Cholera Vaccine, Rotavirus Vaccine</p>\n</div> \n<p><b>Discussion</b> It is recommended that two or more injectable or nasally administered live vaccines not administered on the same day be separated by at least 28 days (ie, 4 weeks).<sup>1</sup> This interval is to minimize the potential risk for immune interference from the vaccine administered first on the vaccine administered later. <br><br>In a retrospective cohort study, the risk for varicella vaccine failure among persons who received varicella vaccine within 28 days of measles-mumps-rubella (MMR) vaccination was threefold higher [adjusted RR: 3.1; 95% CI(1.5 to 6.4)] than among persons who received varicella vaccine greater than 28 days after MMR vaccination.<sup>2</sup> <br><br>The live oral vaccines Ty21a typhoid vaccine and rotavirus vaccine are not believed to interfere with each other and may be administered simultaneously with or at any interval before or after live vaccines (injectable or intranasal).<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Atkinson WL, Pickering LK, Schwartz B, et al. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). <i>MMWR Recomm Rep</i>. 2002;51(RR-2):1-35. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11848294\">[PubMed 11848294]</a></p>\n<p>2. Verstraeten T, Jumaan AO, Mullooly JP, et al. A retrospective cohort study of the association of varicella vaccine failure with asthma, steroid use, age at vaccination, and measles-mumps-rubella vaccination. <i>Pediatrics</i>. 2003;112(2):e98-e103. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12897314\">[PubMed 12897314]</a></p>\n<p>3. Jackson BR, Iqbal S, Mahon B. Updated recommendations for the use of typhoid vaccine--Advisory Committee on Immunization Practices, United States, 2015. <i>MMWR Morb Mortal Wkly Rep</i>. 2015;64(11):305-308. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25811680\">[PubMed 25811680]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11319":"<p><b>Title</b> Anagliptin / Probenecid</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Probenecid may increase the serum concentration of Anagliptin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased anagliptin effects and toxicities if combined with probenecid.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the anagliptin product labeling, probenecid (1,000 mg twice daily) increased the anagliptin (100 mg single dose) AUC and maximum serum concentration 81% and 54%, respectively.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but probenecid-mediated inhibition of the renal transporters involved in anagliptin active tubular secretion (eg, OAT1, OAT3) likely contributes.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Guardlet (anagliptin) 100 mg tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=78860. Accessed March 15, 2017.</p>\n<p>2. Furuta S, Smart C, Hackett A, Benning R, Warrington S. Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans. <i>Xenobiotica</i>. 2013;43(5):432-442. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23075005\">[PubMed 23075005]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11320":"<p><b>Title</b> Digoxin / Anagliptin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Anagliptin may increase the serum concentration of Digoxin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased digoxin concentrations and effects if combined with anagliptin.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the anagliptin product labeling, anagliptin (400 mg daily x 5 days) increased the digoxin (0.25 mg daily) maximum serum concentration and AUC 49% and 18%, respectively.<sup>1</sup><br><br>The mechanism of this interaction is unknown, but competition for P-glycoprotein or other renal transporters may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Guardlet (anagliptin) 100 mg tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=78860. Accessed March 15, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11321":"<p><b>Title</b> Anagliptin / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Anagliptin. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the anagliptin product labeling, cyclosporine (600 mg single dose) increased the anagliptin (400 mg daily) maximum serum concentration and AUC 25% and 20%, respectively.<sup>1</sup><br><br>The mechanism of this interaction has not been fully investigated, but cyclosporine-mediated inhibition of P-glycoprotein, a transporter that may be responsible for anagliptin distribution, may contribute.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Guardlet (anagliptin) 100 mg tablet [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=78860. Accessed March 15, 2017.</p>\n<p>2. Furuta S, Smart C, Hackett A, Benning R, Warrington S. Pharmacokinetics and metabolism of [14C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans. <i>Xenobiotica</i>. 2013;43(5):432-442. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23075005\">[PubMed 23075005]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11322":"<p><b>Title</b> Melatonin / Alcohol (Ethyl)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Alcohol (Ethyl) may enhance the adverse/toxic effect of Melatonin. Alcohol (Ethyl) may diminish the therapeutic effect of Melatonin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid concomitant use of alcohol and melatonin.</p> \n<p><b>Discussion</b> According to melatonin product labeling, alcohol use may reduce the effectiveness of melatonin on sleep and should be avoided.<sup>1</sup> Additionally, alcohol ingested simultaneously with the prolonged-release melatonin product may alter the prolonged release characteristics of the tablet and result in an immediate release of melatonin.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Circadin (melatonin) [summary of product characteristics]. St Leonards, New South Wales: Aspen Pharma Pty Ltd; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11323":"<p><b>Title</b> Melatonin / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Melatonin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased melatonin effects/toxicities if combined with cimetidine.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the melatonin product label, concomitant administration of cimetidine and melatonin increased the melatonin AUC 70%.<sup>1</sup><br><br>The mechanism of this potential interaction has not been investigated, but cimetidine is a weak inhibitor of CYP1A2 and CYP2C19, enzymes responsible for melatonin metabolism.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Circadin (melatonin) [summary of product characteristics]. St Leonards, New South Wales: Aspen Pharma Pty Ltd; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11324":"<p><b>Title</b> Benzodiazepines / Melatonin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Melatonin may enhance the sedative effect of Benzodiazepines. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased sedative effects of benzodiazepines if combined with melatonin.</p>\n<div>\n <p><b>Benzodiazepines Interacting Members</b> ALPRAZolam, Bromazepam, ChlordiazePOXIDE, CloBAZam, ClonazePAM, Clorazepate, DiazePAM, Estazolam, Ethyl Loflazepate, Etizolam, Flunitrazepam, Flurazepam, Loprazolam, LORazepam, Lormetazepam, Midazolam, Nitrazepam, Nordazepam, Oxazepam, Prazepam, Quazepam, Temazepam, Tofisopam, Triazolam</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 16 healthy volunteers, administration of melatonin (2 mg prolonged-release tablet) alone had no effect on attention, memory, or driving abilities.<sup>1</sup> In contrast, administration of zolpidem (10 mg) reduced attention, memory, and driving abilities and these deficits were significantly more pronounced when volunteers received melatonin and zolpidem simultaneously.<sup>1</sup> In another study, 29 participants who received the combination of zolpidem (10 mg) and melatonin (5 mg) for 5 nights experienced greater morning fatigue, more difficulty waking up, and a greater incidence of confusion compared with 34 participants who received zolpidem alone.<sup>2</sup> Participants who received the combination also reported more nausea on day 1 compared with those who received only zolpidem.<sup>2</sup><br><br>Melatonin product labeling states that melatonin may enhance the sedative properties of benzodiazepines and non-benzodiazepine hypnotics and patients should be monitored for such effects.<sup>3</sup><br><br>The mechanism of this interaction has not been investigated, but additive and synergistic effects on sleep induction may contribute.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Otmani S, Demazieres A, Staner C, et al. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. <i>Hum Psychopharmacol</i>. 2008;23(8):693-705. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18763235\">[PubMed 18763235]</a></p>\n<p>2. Suhner A, Schlagenhauf P, Hofer I, Johnson R, Tschopp A, Steffen R. Effectiveness and tolerability of melatonin and zolpidem for the alleviation of jet lag. <i>Aviat Space Environ Med</i>. 2001;72(7):638-646. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11471907\">[PubMed 11471907]</a></p>\n<p>3. Circadin (melatonin) [summary of product characteristics]. St Leonards, New South Wales: Aspen Pharma Pty Ltd; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11325":"<p><b>Title</b> Hypnotics (Nonbenzodiazepine) / Melatonin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Melatonin may enhance the sedative effect of Hypnotics (Nonbenzodiazepine). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased sedative effects of hypnotics if combined with melatonin.</p>\n<div>\n <p><b>Hypnotics (Nonbenzodiazepine) Interacting Members</b> Chloral Betaine, Chloral Hydrate, Eszopiclone, Glutethimide, Ramelteon, Suvorexant, Tasimelteon, Zaleplon, Zolpidem, Zopiclone</p>\n</div> \n<p><b>Discussion</b> In a clinical study of 16 healthy volunteers, administration of melatonin (2 mg prolonged-release tablet) alone had no effect on attention, memory, or driving abilities.<sup>1</sup> In contrast, administration of zolpidem (10 mg) reduced attention, memory, and driving abilities and these deficits were significantly more pronounced when volunteers received melatonin and zolpidem simultaneously.<sup>1</sup> In another study, 29 participants who received the combination of zolpidem (10 mg) and melatonin (5 mg) for 5 nights experienced greater morning fatigue, more difficulty waking up, and a greater incidence of confusion compared with 34 participants who received zolpidem alone.<sup>2</sup> Participants who received the combination also reported more nausea on day 1 compared with those who received only zolpidem.<sup>2</sup><br><br>Melatonin product labeling states that melatonin may enhance the sedative properties of benzodiazepines and non-benzodiazepine hypnotics and patients should be monitored for such effects.<sup>3</sup><br><br>The mechanism of this interaction has not been investigated, but additive and synergistic effects on sleep induction may contribute.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Otmani S, Demazieres A, Staner C, et al. Effects of prolonged-release melatonin, zolpidem, and their combination on psychomotor functions, memory recall, and driving skills in healthy middle aged and elderly volunteers. <i>Hum Psychopharmacol</i>. 2008;23(8):693-705. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18763235\">[PubMed 18763235]</a></p>\n<p>2. Suhner A, Schlagenhauf P, Hofer I, Johnson R, Tschopp A, Steffen R. Effectiveness and tolerability of melatonin and zolpidem for the alleviation of jet lag. <i>Aviat Space Environ Med</i>. 2001;72(7):638-646. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11471907\">[PubMed 11471907]</a></p>\n<p>3. Circadin (melatonin) [summary of product characteristics]. St Leonards, New South Wales: Aspen Pharma Pty Ltd; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11326":"<p><b>Title</b> Thioridazine / Melatonin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Melatonin may enhance the adverse/toxic effect of Thioridazine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased central nervous system effects of thioridazine (eg, âfuzzy-headednessâ) if combined with melatonin.</p> \n<p><b>Discussion</b> According to the melatonin product labeling, when melatonin was coadministered with thioridazine, no clinically significant pharmacokinetic interaction was noted, but increased feelings of âfuzzy-headednessâ compared with thioridazine alone was observed.<sup>1</sup><br><br>The mechanism of this potential interaction is unknown, but may be the result of additive or synergistic central nervous system effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Circadin (melatonin) [summary of product characteristics]. St Leonards, New South Wales: Aspen Pharma Pty Ltd; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11327":"<p><b>Title</b> Imipramine / Melatonin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Melatonin may enhance the adverse/toxic effect of Imipramine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased central nervous system effects of imipramine (eg, feelings of tranquility, difficulty performing tasks) if combined with melatonin.</p> \n<p><b>Discussion</b> According to the melatonin product labeling, when melatonin was coadministered with imipramine, no clinically significant pharmacokinetic interaction was noted, but increased feelings of tranquility and difficulty in performing tasks compared with imipramine alone was observed.<sup>1</sup><br><br>The mechanism of this potential interaction is unknown, but may be the result of additive or synergistic central nervous system effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Circadin (melatonin) [summary of product characteristics]. St Leonards, New South Wales: Aspen Pharma Pty Ltd; June 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11328":"<p><b>Title</b> QuiNIDine / EPHEDrine (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> EPHEDrine (Systemic) may diminish the therapeutic effect of QuiNIDine. QuiNIDine may diminish the therapeutic effect of EPHEDrine (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased ephedrine efficacy if combined with quinidine. Also consider the possibility that ephedrine may diminish the antiarrhythmic efficacy of quinidine.</p> \n<p><b>Discussion</b> In a clinical study of 8 healthy volunteers, the elevation in blood pressure and heart rate after norepinephrine (ephedrine works by simulating the release of norepinephrine stores) infusions (0.075 mcg/kg/min and 0.15 mcg/kg/min) was significantly blunted in the presence of intravenous quinidine (200 mg given over 20 minutes).<sup>1</sup> Additionally, the closely related drug epinephrine, has been reported to diminish the antiarrhythmic efficacy of quinidine.<sup>2,3,4</sup><br><br>Ephedrine prescribing information states that quinidine may antagonize the pressor effects of ephedrine and that patients should have their blood pressure and response to ephedrine monitored closely if these agents are combined.<sup>5</sup><br><br>The suspected mechanism of this interaction is a result of the alpha-adrenergic blocking effects of quinidine opposing the alpha-adrenergic stimulatory effects of ephedrine.<sup>5,6</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Schmid PG, Nelson LD, Mark AL, Heistad DD, Abboud FM. Inhibition of adrenergic vasoconstriction by quinidine. <i>J Pharmacol Exp Ther</i>. 1974;188(1):124-134. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4358435\">[PubMed 4358435]</a></p>\n<p>2. Calkins H, Sousa J, el-Atassi R, Schmaltz S, Kadish A, Morady F. Reversal of antiarrhythmic drug effects by epinephrine: quinidine versus amiodarone. <i>J Am Coll Cardiol</i>. 1992;19(2):347-352. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1732363\">[PubMed 1732363]</a></p>\n<p>3. Morady F, Kou WH, Kadish AH, Toivonen LK, Kushner JA, Schmaltz S. Effects of epinephrine in patients with an accessory atrioventricular connection treated with quinidine. <i>Am J Cardiol</i>. 1988;62(9):580-584. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3414550\">[PubMed 3414550]</a></p>\n<p>4. Morady F, Kou WH, Kadish AH, et al. Antagonism of quinidine's electrophysiologic effects by epinephrine in patients with ventricular tachycardia. <i>J Am Coll Cardiol</i>. 1988;12(2):388-394. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3392332\">[PubMed 3392332]</a></p>\n<p>5. Akovaz (ephedrine) injection [prescribing information]. Chesterfield, MO: Eclat Pharmaceuticals; April 2016.</p>\n<p>6. Quinidine gluconate extended-release tablets [prescribing information]. Philadelphia, PA: Mutual Pharmaceutical Company Inc; August 2009.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11329":"<p><b>Title</b> QuiNIDine / EPHEDrine (Nasal)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> EPHEDrine (Nasal) may diminish the therapeutic effect of QuiNIDine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for decreased quinidine efficacy (ie, arrhythmias) if combined with ephedrine nasal drops.</p> \n<p><b>Discussion</b> Although no studies have evaluated the interaction between ephedrine and quinidine, a related drug, epinephrine (given intravenously), has been shown to diminish the antiarrhythmic effect of quinidine in several studies.<sup>1,2,3</sup><br><br>Product labeling for ephedrine nasal drops states that the use of ephedrine may increase the risk of arrhythmias when combined with quinidine.<sup>4</sup><br><br>The mechanism of this potential interaction has not been fully investigated, but excessive adrenergic stimulation by epinephrine (and possibly ephedrine) is likely arrhythmogenic and may negate the antiarrhythmic effects of quinidine.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Calkins H, Sousa J, el-Atassi R, Schmaltz S, Kadish A, Morady F. Reversal of antiarrhythmic drug effects by epinephrine: quinidine versus amiodarone. <i>J Am Coll Cardiol</i>. 1992;19(2):347-352. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1732363\">[PubMed 1732363]</a></p>\n<p>2. Morady F, Kou WH, Kadish AH, Toivonen LK, Kushner JA, Schmaltz S. Effects of epinephrine in patients with an accessory atrioventricular connection treated with quinidine. <i>Am J Cardiol</i>. 1988;62(9):580-584. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3414550\">[PubMed 3414550]</a></p>\n<p>3. Morady F, Kou WH, Kadish AH, et al. Antagonism of quinidine's electrophysiologic effects by epinephrine in patients with ventricular tachycardia. <i>J Am Coll Cardiol</i>. 1988;12(2):388-394. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3392332\">[PubMed 3392332]</a></p>\n<p>4. Ephedrine nasal drops [summary of prescribing characteristics]. Huddersfield, West Yorks, United Kingdom: Thorton &amp; Ross Ltd; March 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11330":"<p><b>Title</b> Simeprevir / Daclatasvir</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Daclatasvir may increase the serum concentration of Simeprevir. Simeprevir may increase the serum concentration of Daclatasvir. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> According to prescribing information, dosage adjustments of either simeprevir or daclatasvir are unnecessary with concomitant therapy, although there were pharmacokinetic changes for both drugs.<sup>1</sup> In 24 healthy volunteers, simeprevir (60 mg 150 mg daily for 7 days) AUC and maximum serum concentration increased by 44% and 39%. Daclatasvir (60 mg daily for 7 days) AUC and maximum serum concentration also increased by 96% and 50%, respectively. This combination is well-tolerated with no serious adverse effects in healthy volunteers and patients with chronic hepatitis C.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Olysio (simeprevir) [prescribing information]. Titusville, NJ: Janssen Therapeutics; May 2017.</p>\n<p>2. Zeuzem S, Hezode C, Bronowicki J-P, et al. Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection. <i>J Hepatol</i> 64;2:292-300. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2645396\">[PubMed 2645396]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11331":"<p><b>Title</b> Melatonin / Estrogen Derivatives</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Estrogen Derivatives may increase the serum concentration of Melatonin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Estrogen Derivatives Interacting Members</b> Diethylstilbestrol, Estradiol (Systemic), Estradiol (Topical), Estriol (Systemic), Estriol (Topical), Estrogens (Conjugated A/Synthetic), Estrogens (Conjugated B/Synthetic), Estrogens (Conjugated/Equine, Systemic), Estrogens (Conjugated/Equine, Topical), Estrogens (Esterified), Estrone, Estropipate, Ethinyl Estradiol, Mestranol, Polyestradiol, Tibolone</p>\n</div> \n<p><b>Discussion</b> No studies have evaluated the effects of estrogen derivatives on melatonin pharmacokinetics. Melatonin product labeling states that use of estrogens may increase melatonin concentrations by inhibiting CYP1A2, an enzyme responsible for melatonin metabolism.<sup>1</sup> Many estrogens have not been implicated as CYP1A2 inhibitors and while others (eg, ethinyl estradiol, estradiol, conjugated estrogens) do show some inhibitory effects on CYP1A2, the majority of the data suggest that they are only weak inhibitors.<sup>2,3,4,5,6</sup> The clinical relevance of a small increase in melatonin exposure is unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Circadin (melatonin) [summary of product characteristics]. St Leonards, New South Wales: Aspen Pharma Pty Ltd; June 2016.</p>\n<p>2. O'Connell MB, Frye RF, Matzke GR, et al. Effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women. <i>J Clin Pharmacol</i>. 2006;46(11):1299-1307. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17050794\">[PubMed 17050794]</a></p>\n<p>3. Pollock BG, Wylie M, Stack JA, et al. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. <i>J Clin Pharmacol</i>. 1999;39(9):936-940. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10471985\">[PubMed 10471985]</a></p>\n<p>4. Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. <i>Eur J Clin Pharmacol</i>. 1985;28(4):425-428. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4029248\">[PubMed 4029248]</a></p>\n<p>5. Gardner MJ, Tornatore KM, Jusko WJ, Kanarkowski R. Effects of tobacco smoking and oral contraceptive use on theophylline disposition. <i>Br J Clin Pharmacol</i>. 1983;16(3):271-280. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6626419\">[PubMed 6626419]</a></p>\n<p>6. Tornatore KM, Kanarkowski R, McCarthy EL, Gardner MJ, Yurchak AM, Jusko WJ. Effect of chronic oral contraceptive steroids on theophylline disposition. <i>Eur J Clin Pharmacol</i>. 1982;23(2):129-134. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7140802\">[PubMed 7140802]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11332":"<p><b>Title</b> Oxytocin / Gemeprost</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Gemeprost may enhance the adverse/toxic effect of Oxytocin. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> The concomitant use of gemeprost and labor inducers, such as oxytocin, is not recommended. Monitor uterine activity closely if used sequentially.</p> \n<p><b>Discussion</b> Cases of uterine rupture with concurrent administration of gemeprost and oxytocin have been reported.<sup>1,2</sup> Gemeprost product labeling states that because labor inducers/accelerators (ie, oxytocin) can potentiate the action of gemeprost and their concurrent use is not recommended.<sup>3,4,5</sup><br><br>The mechanism by which oxytocin and gemeprost increase the risk of uterine rupture is not fully understood, but both induce myometrial contractility. Prostaglandin E1 analogs are also involved in softening and dilation of cervical tissue.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Vine SJ, Prys-Davies A, Pearson JF. Transverse posterior cervicoisthmic rupture after gemeprost pessaries for termination. <i>BMJ</i>. 1992;305(6865):1332. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1483081\">[PubMed 1483081]</a></p>\n<p>2. Thong KJ, Baird DT. Uterine rupture in midtrimester abortion. A complication of gemeprost vaginal pessaries and oxytocin. Case report. <i>Br J Obstet Gynaecol</i>. 1991;98(4):416. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2031905\">[PubMed 2031905]</a></p>\n<p>3. Cervagem (gemeprost) [prescribing information]. Macquarie Park, New South Wales, Australia: sanofi-aventis australia pty ltd; December 2016.</p>\n<p>4. Cervagem (gemeprost) [Singapore prescribing information]. Anagni, Italy: Sanofi SPA; June 2016.</p>\n<p>5. Cervagem (gemeprost) [UK summary of prescribing characteristics]. Guildford, Surrey, United Kingdom: Aventis Pharma Limited; January 2014.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11333":"<p><b>Title</b> Sirolimus / Calcium Channel Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Calcium Channel Blockers may enhance the adverse/toxic effect of Sirolimus. Specifically, the risk of angioedema may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Calcium Channel Blockers Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Bepridil, Cilnidipine, Clevidipine, DilTIAZem, Efonidipine, Felodipine, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Verapamil</p>\n</div> \n<p><b>Discussion</b> The prescribing information for temsirolimus recommends monitoring for evidence of angioedema when used with an angiotensin converting enzyme (ACE) inhibitor or calcium channel blocker (CCB) due to reports of angioedema associated with combined use of an mammalian target of rapamycin (mTOR) inhibitor and either the ACE inhibitor ramipril or the CCB amlodipine.<sup>1</sup> The labeling for other mTOR inhibitors also state that angioedema has been reported with their use,<sup>2,3</sup> although neither specifically mentions a particular risk with CCBs.<br><br>Several studies have reported a low incidence of angioedema with use of CCBs. In the ALLHAT trial (n=42,418) the amlodipine group (n=9048) represented 6% of the 0.125% of patients overall who developed angioedema.<sup>4,5</sup> A retrospective study of Medicare recipients in 3 states reported angioedema rates of 0.4% to 1.1% in patients taking CCBs (n=159,133).<sup>6</sup> <br><br>In a systematic review of polycystic kidney disease therapy, 3 studies (n=2039) reported increased risk of angioedema with sirolimus (RR=5 to 17.3) and everolimus (RR=25.4).<sup>7</sup> In a small cross-sectional study of renal transplant recipients (n=80), 15% developed angioedema (mostly facial involvement) while taking sirolimus.<sup>8</sup> Two case reports of 5 patients reported angioedema associated with sirolimus, and it was noted that 2 patients were also taking amlodipine.<sup>9,10</sup><br><br>The specific mechanisms by which both CCBs and mTOR inhibitors increase the risk of angioedema are still unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Torisel (temsirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; May 2017.</p>\n<p>2. Zortress (everolimus) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2016.</p>\n<p>3. Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; April 2017.</p>\n<p>4. Roe N, Twilla JD, Duhart B, Wheeler B. Breast cancer patient with everolimus-induced angioedema: A rare occurrence with potential for serious consequences. <i>J Oncol Pharm Pract</i>. 2017;23(4):318-320. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27000278\">[PubMed 27000278]</a></p>\n<p>5. Bolignano D, Palmer SC, Ruospo M, Zoccali C, Craig JC, Strippoli GF. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. <i>Cochrane Database Syst Rev</i>. 2015;(7):CD010294. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26171904\">[PubMed 26171904]</a></p>\n<p>6. Andersen LK, Jensen JE, Bygum A. Second episode of near-fatal angioedema in a patient treated with everolimus. <i>Ann Allergy Asthma Immunol</i>. 2015;115(2):152-153. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26081314\">[PubMed 26081314]</a></p>\n<p>7. Southward J, Irvine E, Rabinovich M. Probable amlodipine-induced angioedema. <i>Ann Pharmacother</i>. 2009;43(4):772-776. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19299323\">[PubMed 19299323]</a></p>\n<p>8. Burkhart DG, Brown NJ, Griffin MR, Ray WA, Hammerstrom T, Weiss S. Angiotensin converting enzyme inhibitor-associated angioedema: higher risk in blacks than whites. <i>Pharmacoepidemiol Drug Saf</i>. 1996;5(3):149-154. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15073831\">[PubMed 15073831]</a></p>\n<p>9. Romano A, Pietrantonio F, Garcovich A, et al. Delayed hypersensitivity to diltiazem in two patients. <i>Ann Allergy</i>. 1992;69(1):31-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1626756\">[PubMed 1626756]</a></p>\n<p>10. Sadick NS, Katz AS, Schreiber TL. Angioedema from calcium channel blockers. <i>J Am Acad Dermatol</i>. 1989;21(1):132-133. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2745759\">[PubMed 2745759]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11334":"<p><b>Title</b> Temsirolimus / Calcium Channel Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Calcium Channel Blockers may enhance the adverse/toxic effect of Temsirolimus. Specifically, the risk of angioedema may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Calcium Channel Blockers Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Bepridil, Cilnidipine, Clevidipine, DilTIAZem, Efonidipine, Felodipine, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Verapamil</p>\n</div> \n<p><b>Discussion</b> The prescribing information for temsirolimus recommends monitoring for evidence of angioedema when used with an angiotensin converting enzyme (ACE) inhibitor or calcium channel blocker (CCB) due to reports of angioedema associated with combined use of an mammalian target of rapamycin (mTOR) inhibitor and either the ACE inhibitor ramipril or the CCB amlodipine.<sup>1</sup> The labeling for other mTOR inhibitors also state that angioedema has been reported with their use,<sup>2,3</sup> although neither specifically mentions a particular risk with CCBs.<br><br>Several studies have reported a low incidence of angioedema with use of CCBs. In the ALLHAT trial (n=42,418) the amlodipine group (n=9048) represented 6% of the 0.125% of patients overall who developed angioedema.<sup>4,5</sup> A retrospective study of Medicare recipients in 3 states reported angioedema rates of 0.4% to 1.1% in patients taking CCBs (n=159,133).<sup>6</sup> <br><br>In a systematic review of polycystic kidney disease therapy, 3 studies (n=2039) reported increased risk of angioedema with sirolimus (RR=5 to 17.3) and everolimus (RR=25.4).<sup>7</sup> In a small cross-sectional study of renal transplant recipients (n=80), 15% developed angioedema (mostly facial involvement) while taking sirolimus.<sup>8</sup> Two case reports of 5 patients reported angioedema associated with sirolimus, and it was noted that 2 patients were also taking amlodipine.<sup>9,10</sup><br><br>The specific mechanisms by which both CCBs and mTOR inhibitors increase the risk of angioedema are still unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Torisel (temsirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; May 2017.</p>\n<p>2. Zortress (everolimus) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2016.</p>\n<p>3. Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; April 2017.</p>\n<p>4. Roe N, Twilla JD, Duhart B, Wheeler B. Breast cancer patient with everolimus-induced angioedema: A rare occurrence with potential for serious consequences. <i>J Oncol Pharm Pract</i>. 2017;23(4):318-320. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27000278\">[PubMed 27000278]</a></p>\n<p>5. Bolignano D, Palmer SC, Ruospo M, Zoccali C, Craig JC, Strippoli GF. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. <i>Cochrane Database Syst Rev</i>. 2015;(7):CD010294. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26171904\">[PubMed 26171904]</a></p>\n<p>6. Andersen LK, Jensen JE, Bygum A. Second episode of near-fatal angioedema in a patient treated with everolimus. <i>Ann Allergy Asthma Immunol</i>. 2015;115(2):152-153. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26081314\">[PubMed 26081314]</a></p>\n<p>7. Southward J, Irvine E, Rabinovich M. Probable amlodipine-induced angioedema. <i>Ann Pharmacother</i>. 2009;43(4):772-776. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19299323\">[PubMed 19299323]</a></p>\n<p>8. Burkhart DG, Brown NJ, Griffin MR, Ray WA, Hammerstrom T, Weiss S. Angiotensin converting enzyme inhibitor-associated angioedema: higher risk in blacks than whites. <i>Pharmacoepidemiol Drug Saf</i>. 1996;5(3):149-154. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15073831\">[PubMed 15073831]</a></p>\n<p>9. Romano A, Pietrantonio F, Garcovich A, et al. Delayed hypersensitivity to diltiazem in two patients. <i>Ann Allergy</i>. 1992;69(1):31-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1626756\">[PubMed 1626756]</a></p>\n<p>10. Sadick NS, Katz AS, Schreiber TL. Angioedema from calcium channel blockers. <i>J Am Acad Dermatol</i>. 1989;21(1):132-133. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2745759\">[PubMed 2745759]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11335":"<p><b>Title</b> Everolimus / Calcium Channel Blockers</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Calcium Channel Blockers may enhance the adverse/toxic effect of Everolimus. Specifically, the risk of angioedema may be increased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Calcium Channel Blockers Interacting Members</b> AmLODIPine, Barnidipine, Benidipine, Bepridil, Cilnidipine, Clevidipine, DilTIAZem, Efonidipine, Felodipine, Isradipine, Lacidipine, Lercanidipine, Manidipine, NiCARdipine, NIFEdipine, Nilvadipine, NiMODipine, Nisoldipine, Nitrendipine, Verapamil</p>\n</div> \n<p><b>Discussion</b> The prescribing information for temsirolimus recommends monitoring for evidence of angioedema when used with an angiotensin converting enzyme (ACE) inhibitor or calcium channel blocker (CCB) due to reports of angioedema associated with combined use of an mammalian target of rapamycin (mTOR) inhibitor and either the ACE inhibitor ramipril or the CCB amlodipine.<sup>1</sup> The labeling for other mTOR inhibitors also state that angioedema has been reported with their use,<sup>2,3</sup> although neither specifically mentions a particular risk with CCBs.<br><br>Several studies have reported a low incidence of angioedema with use of CCBs. In the ALLHAT trial (n=42,418) the amlodipine group (n=9048) represented 6% of the 0.125% of patients overall who developed angioedema.<sup>4,5</sup> A retrospective study of Medicare recipients in 3 states reported angioedema rates of 0.4% to 1.1% in patients taking CCBs (n=159,133).<sup>6</sup> <br><br>In a systematic review of polycystic kidney disease therapy, 3 studies (n=2039) reported increased risk of angioedema with sirolimus (RR=5 to 17.3) and everolimus (RR=25.4).<sup>7</sup> In a small cross-sectional study of renal transplant recipients (n=80), 15% developed angioedema (mostly facial involvement) while taking sirolimus.<sup>8</sup> Two case reports of 5 patients reported angioedema associated with sirolimus, and it was noted that 2 patients were also taking amlodipine.<sup>9,10</sup><br><br>The specific mechanisms by which both CCBs and mTOR inhibitors increase the risk of angioedema are still unknown.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Torisel (temsirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; May 2017.</p>\n<p>2. Zortress (everolimus) [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; October 2016.</p>\n<p>3. Rapamune (sirolimus) [prescribing information]. Philadelphia, PA: Wyeth Pharmaceuticals Inc; April 2017.</p>\n<p>4. Roe N, Twilla JD, Duhart B, Wheeler B. Breast cancer patient with everolimus-induced angioedema: A rare occurrence with potential for serious consequences. <i>J Oncol Pharm Pract</i>. 2017;23(4):318-320. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27000278\">[PubMed 27000278]</a></p>\n<p>5. Bolignano D, Palmer SC, Ruospo M, Zoccali C, Craig JC, Strippoli GF. Interventions for preventing the progression of autosomal dominant polycystic kidney disease. <i>Cochrane Database Syst Rev</i>. 2015;(7):CD010294. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26171904\">[PubMed 26171904]</a></p>\n<p>6. Andersen LK, Jensen JE, Bygum A. Second episode of near-fatal angioedema in a patient treated with everolimus. <i>Ann Allergy Asthma Immunol</i>. 2015;115(2):152-153. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26081314\">[PubMed 26081314]</a></p>\n<p>7. Southward J, Irvine E, Rabinovich M. Probable amlodipine-induced angioedema. <i>Ann Pharmacother</i>. 2009;43(4):772-776. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19299323\">[PubMed 19299323]</a></p>\n<p>8. Burkhart DG, Brown NJ, Griffin MR, Ray WA, Hammerstrom T, Weiss S. Angiotensin converting enzyme inhibitor-associated angioedema: higher risk in blacks than whites. <i>Pharmacoepidemiol Drug Saf</i>. 1996;5(3):149-154. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15073831\">[PubMed 15073831]</a></p>\n<p>9. Romano A, Pietrantonio F, Garcovich A, et al. Delayed hypersensitivity to diltiazem in two patients. <i>Ann Allergy</i>. 1992;69(1):31-32. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1626756\">[PubMed 1626756]</a></p>\n<p>10. Sadick NS, Katz AS, Schreiber TL. Angioedema from calcium channel blockers. <i>J Am Acad Dermatol</i>. 1989;21(1):132-133. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2745759\">[PubMed 2745759]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11336":"<p><b>Title</b> Erythropoiesis-Stimulating Agents / Angiotensin-Converting Enzyme Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Angiotensin-Converting Enzyme Inhibitors may diminish the therapeutic effect of Erythropoiesis-Stimulating Agents. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Existing data/reports are inconsistent </p> \n<p><b>Patient Management</b> No action needed.</p>\n<div>\n <p><b>Angiotensin-Converting Enzyme Inhibitors Interacting Members</b> Alacepril, Benazepril, Captopril, Cilazapril, Enalapril, Enalaprilat, Fosinopril, Imidapril, Lisinopril, Moexipril, Perindopril, Quinapril, Ramipril, Trandolapril, Zofenopril</p>\n <p><b>Erythropoiesis-Stimulating Agents Interacting Members</b> Darbepoetin Alfa, Epoetin Alfa, Epoetin Beta, Epoetin Lambda, Epoetin Zeta, Methoxy Polyethylene Glycol-Epoetin Beta</p>\n</div> \n<p><b>Discussion</b> Several cohort studies and prospective randomized trials (n=5 to n=1,305) of hemodialysis patients have reported an apparent relative resistance to erythropoiesis-stimulating agents (ESA) in patients concurrently taking angiotensin converting enzyme (ACE) inhibitors.<sup>1,2,3,4,5,6,7,8,9,10,11,12,13</sup> One retrospective study (n=40) reported a significant increase in ESA requirement, to more than twice the dose, after 15 months for patients taking an ESA and an ACE inhibitor compared to use of an ESA alone.<sup>7</sup> Another small study (n=5), found that ACE inhibitor use was associated with significantly increased recombinant human erythropoietin dose requirements and reduced hemoglobin over one year. The mean weekly dose increased from 4,400 units at baseline to 8,600 units at 12 months in the ACE inhibitor-treated group vs. 4,600 units at baseline and 4,200 units at 12 months in the control group.<sup>9</sup> Another cross-sectional study reported significantly higher ESA requirements in patients taking both an ESA and an ACE inhibitor vs. those using an ESA alone (56 vs. 36 IU/kg/HD session, respectively).<sup>12</sup> In a large study of type 2 diabetics (n=1,015), ACE inhibitor therapy was associated with ESA resistance in a univariate analysis, though the association was statistically insignificant [OR=1.27 (95% CI: 0.96 to 1.69)].<sup>13</sup> A multivariate analysis revealed a generally similar association with ACE inhibitor therapy [OR=1.32 (95% CI: 0.98 to 1.78)].<br><br>In contrast, other clinical outcome studies (n=12 to n=2,213) have reported minimal or no evidence of ESA resistance with concurrent use of ACE inhibitors and ESAs.<sup>14,15, 16,17,18,19,20,21,22,23</sup><br><br>The mechanism for this potential drug interaction has not been fully investigated. The renin-angiotensin system (RAS) appears to be involved in regulation of endogenous erythropoietin production, with activation of RAS leading to enhanced production of endogenous erythropoietin.<sup>22,23</sup>. The full impact of RAS alteration on response to or dose requirements of exogenous ESAs is not fully understood.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Schiffl H, Bergner A. Angiotensin-II, renal anemia and hyporesponsiveness to recombinant human erythropoietin. <i>Int J Artif Organs</i>. 1999;22(10):672-675. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10585130\">[PubMed 10585130]</a></p>\n<p>2. Guerrero-Riscos MA, Montes-Delgado R, Seda-Guzman M, Praena-Fernandez JM. Erythropoietin resistance and survival in non-dialysis patients with stage 4-5 chronic kidney disease and heart disease. <i>Nefrologia</i>. 2012;32(3):343-352.<a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22535158\">[PubMed 22535158]</a></p>\n<p>3. Mallick S, Rafiroiu A, Kanthety R, Iqbal S, Malik R, Rahman M. Factors predicting erythropoietin resistance among maintenance hemodialysis patients. <i>Blood Purif</i>. 2012;33(4):238-244. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22378310\">[PubMed 22378310]</a></p>\n<p>4. Qureshi IZ, Abid K, Ambreen F, Qureshi AL. Angiotensin converting enzyme inhibitors impair recombinant human erythropoietin induced erythropoiesis in patients with chronic renal failure. <i>Saudi Med J</i>. 2007;28(2):193-196. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17268695\">[PubMed 17268695]</a></p>\n<p>5. Grzegorzewska AE. Erythropoietin dose and angiotensin-converting enzyme inhibitors. <i>Perit Dial Int</i>. 2007;27(1):102-103. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17179526\">[PubMed 17179526]</a></p>\n<p>6. Garrett PJ, Stewart L, Leary J, Lappin TR. Differential manipulation of the renin angiotensin system and epoietin requirements in maintenance haemodialysis patients. <i>Nephrol Dial Transplant</i>. 2001;16(9):1954-1955. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11522893\">[PubMed 11522893]</a></p>\n<p>7. Hess E, Sperschneider H, Stein G. Do ACE inhibitors influence the dose of human recombinant erythropoietin in dialysis patients? <i>Nephrol Dial Transplant</i>. 1996;11(4):749-751. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8671881\">[PubMed 8671881]</a></p>\n<p>8. Navarro JF, Mora C, Rivero A. Effect of angiotensin-converting enzyme inhibitors on hematological parameters and recombinant human erythropoietin doses in peritoneal dialysis patients. <i>Nephron</i>. 1998;80(2):239. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9736830\">[PubMed 9736830]</a></p>\n<p>9. Navarro JF, Macia ML, Mora-Fernandez C, et al. Effects of angiotensin-converting enzyme inhibitors on anemia and erythropoietin requirements in peritoneal dialysispatients. <i>Adv Perit Dial</i>. 1997;13:257-259. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9360694\">[PubMed 9360694]</a></p>\n<p>10. Matsumura M, Nomura H, Koni I, Mabuchi H. Angiotensin-converting enzyme inhibitors are associated with the need for increased recombinant human erythropoietin maintenance doses in hemodialysis patients. Risks of Cardiac Disease in Dialysis Patients Study Group. <i>Nephron</i>. 1997;77(2):164-168. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9346382\">[PubMed 9346382]</a></p>\n<p>11. Gossmann J, Thurmann P, Bachmann T, et al. Mechanism of angiotensin converting enzyme inhibitor-related anemia in renal transplant recipients. <i>Kidney Int</i>. 1996;50(3):973-978. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8872973\">[PubMed 8872973]</a></p>\n<p>12. Dhondt AW, Vanholder RC, Ringoir SM. Angiotensin-converting enzyme inhibitors and higher erythropoietin requirement in chronic haemodialysis patients. <i>Nephrol Dial Transplant</i>. 1995;10(11):2107-2109. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8643177\">[PubMed 8643177]</a></p>\n<p>13. Schneider A, Schneider MP, Scharnagl H, Jardine AG, Wanner C, Drechsler C. Predicting erythropoietin resistance in hemodialysis patients with type 2 diabetes. <i>BMC Nephrol</i>. 2013;14:67. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23521816\">[PubMed 23521816]</a></p>\n<p>14. Winnicki W, Prehslauer A, Kletzmayr J, et al. Lisinopril pharmacokinetics and erythropoietin requirement in hemodialysis patients. <i>Eur J Clin Invest</i>. 2012;42(10):1087-1093. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22845880\">[PubMed 22845880]</a></p>\n<p>15. Yano S, Suzuki K, Iwamoto M, et al. Association between erythropoietin requirements and antihypertensive agents. <i>Nephron Clin Pract</i>. 2008;109(1):c33-39. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=18506108\">[PubMed 18506108]</a></p>\n<p>16. Saudan P, Halabi G, Perneger T, Wasserfallen JB, Wauters JP, Martin PY; Western Switzerland Dialysis Group. ACE inhibitors or angiotensin II receptor blockers in dialysed patients and erythropoietin resistance. <i>J Nephrol</i>. 2006;19(1):91-96. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16523432\">[PubMed 16523432]</a></p>\n<p>17. Varagunam M, McCloskey DJ, Sinnott PJ, Raftery MJ, Yaqoob MM. Angiotensin-converting enzyme gene polymorphism and erythropoietin requirement. <i>Perit Dial Int</i>. 2003;23(2):111-115. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12713075\">[PubMed 12713075]</a></p>\n<p>18. Hayashi K, Hasegawa K, Kobayashi S. Effects of angiotensin-converting enzyme inhibitors on the treatment of anemia with erythropoietin. <i>Kidney Int</i>. 2001;60(5):1910-1916. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11703610\">[PubMed 11703610]</a></p>\n<p>19. Charytan C, Goldfarb-Rumyantzev A, Wang YF, Schwenk MH, Spinowitz BS. Effect of angiotensin-converting enzyme inhibitors on response to erythropoietin therapy in chronic dialysis patients. <i>Am J Nephrol</i>. 1998;18(6):498-503. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9845824\">[PubMed 9845824]</a></p>\n<p>20. Schwenk MH, Jumani AQ, Rosenberg CR, Kulogowski JE, Charytan C, Spinowitz BS. Potential angiotensin-converting enzyme inhibitor-epoetin alfa interaction in patients receiving chronic hemodialysis. <i>Pharmacotherapy</i>. 1998;18(3):627-630. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9620114\">[PubMed 9620114]</a></p>\n<p>21. Conlon PJ, Albers F, Butterly D, Schwab SJ. ACE inhibitors do not affect erythropoietin efficacy in haemodialysis patients. <i>Nephrol Dial Transplant</i>. 1994;9(9):1358. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7816313\">[PubMed 7816313]</a></p>\n<p>22. Kim YC, Mungunsukh O, McCart EA, Roehrich PJ, Yee DK, Day RM. Mechanism of erythropoietin regulation by angiotensin II. <i>Mol Pharmacol</i>. 2014;85(6):898-908. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24695083\">[PubMed 24695083]</a></p>\n<p>23. Hubert C, Savary K, Gasc JM, Corvol P. The hematopoietic system: a new niche for the renin-angiotensin system. <i>Nat Clin Pract Cardiovasc Med</i>. 2006;3(2):80-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16446776\">[PubMed 16446776]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11337":"<p><b>Title</b> Pioglitazone / Topiramate</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Topiramate may decrease the serum concentration of Pioglitazone. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor patients for decreased pioglitazone effects (ie, hyperglycemia) if combined with topiramate.</p> \n<p><b>Discussion</b> Concomitant administration of topiramate and pioglitazone decreased systemic exposure to pioglitazone by 15% in a study of subjects (n=52) receiving pioglitazone 30 mg/day and topiramate titrated to 96 mg/day.<sup>1</sup> Pioglitazone active metabolites M-III and M-IV were decreased by 60% and 15%, respectively. At steady state, pioglitazone had no effect on topiramate pharmacokinetics. When topiramate was added to pioglitazone therapy mild hypokalemia of unknown clinical significance was observed. The study dose of topiramate (96 mg/day) was on the lower side, and it is not known if a higher dose would exhibit a greater effect.<br><br>The pioglitazone prescribing information states that the clinical relevance of this decrease in pioglitazone exposure is unknown; however glycemic control should be monitored closely if these agents are combined.<sup>2</sup><br><br>The specific mechanism for this apparent interaction is uncertain.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Manitpisitkul P, Curtin CR, Shalayda K, Wang SS, Ford L, Heald D. Pharmacokinetic interactions between topiramate and pioglitazone and metformin. <i>Epilepsy Res</i>. 2014;108(9):1519-1532. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25219351\">[PubMed 25219351]</a></p>\n<p>2. Actos (pioglitazone) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; December 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11338":"<p><b>Title</b> Aminolevulinic Acid (Topical) / Photosensitizing Agents</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor patients for evidence of enhanced photosensitivity when aminolevulinic acid is used with other photosensitizing agents.</p>\n<div>\n <p><b>Photosensitizing Agents Interacting Members</b> Aceclofenac, Acemetacin, Acitretin, Adapalene, Afatinib, Afloqualone, Alitretinoin (Systemic), Alitretinoin (Topical), Aminolevulinic Acid (Systemic), Aminolevulinic Acid (Topical), Amiodarone, Bendroflumethiazide, Bexarotene (Systemic), Bexarotene (Topical), Bicalutamide, Calcitriol (Topical), Celecoxib, Chlorothiazide, ChlorproMAZINE, ChlorproPAMIDE, Chlorthalidone, Ciprofloxacin (Systemic), Cobimetinib, Cyclopenthiazide, Demeclocycline, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Dong Quai, Doxycycline, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, FluPHENAZine, Flurbiprofen (Systemic), Gemifloxacin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Griseofulvin, HydroCHLOROthiazide, Hydroflumethiazide, Ibuprofen, Ibuprofen (Topical), Indapamide, Indomethacin, ISOtretinoin (Systemic), Isotretinoin (Topical), Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lomefloxacin, Lornoxicam, Loxoprofen, Lymecycline, Meclofenamate, Mefenamic Acid, Meloxicam, Methotrimeprazine, Methyclothiazide, MetOLazone, Minocycline, Morniflumate, Moxifloxacin (Systemic), Nabumetone, Nadifloxacin, Nalidixic Acid, Naproxen, Nimesulide, Norfloxacin, Ofloxacin (Systemic), Oxaprozin, Oxytetracycline, Panitumumab, Parecoxib, Pelubiprofen, Periciazine, Perphenazine, Phenylbutazone, Pipemidic Acid, Pipotiazine, Pirfenidone, Piroxicam (Systemic), Piroxicam (Topical), Porfimer, Prochlorperazine, Promazine, Propyphenazone, Simeprevir, Sparfloxacin, St John's Wort, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, Sulindac, Talniflumate, Tenoxicam, Tetracycline (Systemic), Thioridazine, Tiaprofenic Acid, TOLAZamide, TOLBUTamide, Tolfenamic Acid, Tolmetin, Tretinoin (Systemic), Tretinoin (Topical), Trifluoperazine, Vemurafenib, Verteporfin, Voriconazole, Xipamide, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> The labeling for topical aminolevulinic acid products caution that concurrent use with other photosensitizing agents may enhance the photosensitivity reaction.<sup>1,2,3</sup> One case report describes a patient taking St Johns wort who experienced a severe photosensivity reaction after treatment with aminolevulinic acid.<sup>4</sup> Australian labeling specifically recommends discontinuation of the photosensitizer St Johns wort 2 weeks prior to treatment with aminolevulinic acid.<sup>3</sup> The individual drugs listed herein as being photosensitizing agents are included primarily based on the findings of published analyses/reviews and individual drug labeling information.<sup>5,6,7</sup><br><br>The proposed mechanism for this potential interaction is additive phototoxicity between aminolevulinic acid and other photosensitizing agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Ameluz (aminolevulinic acid) gel [prescribing information]. Wakefield, MA: Biofrontera Inc; May 2016.</p>\n<p>2. Levulan (aminolevulinic acid) topical solution [prescribing information]. Wilmington, MA: DUSA Pharmaceuticals Inc; March 2010.</p>\n<p>3. Alacare (aminolevulinic acid) dermal patch [summary of product characteristics]. Warriewood, New South Wales, Australia: Link Medical Products; March 2015. </p>\n<p>4. Ladner DP, Klein SD, Steiner RA, Walt H. Synergistic toxicity of delta-aminolaevulinic acid-induced protoporphyrin IX used for photodiagnosis and hypericum extract, a herbal antidepressant. <i>Br J Dermatol</i>. 2001;144(4):916-918. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11298571\">[PubMed 11298571]</a></p>\n<p>5. Naldi L, Conforti A, Venegoni M, et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. <i>Br J Clin Pharmacol</i>. 1999;48(6):839-846. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10594488\">[PubMed 10594488]</a></p>\n<p>6. Lankerani L, Baron ED. Photosensitivity to exogenous agents. <i>J Cutan Med Surg</i>. 2004;8(6):424-431. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15988550\">[PubMed 15988550]</a></p>\n<p>7. Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. <i>Drug Saf</i>. 2011;34(10):821-837. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21879777\">[PubMed 21879777]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11339":"<p><b>Title</b> Aminolevulinic Acid (Systemic) / Photosensitizing Agents</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid administration of other photosensitizing agents within 24 hours before or 24 hours after orally administered aminolevulinic acid.</p>\n<div>\n <p><b>Photosensitizing Agents Interacting Members</b> Aceclofenac, Acemetacin, Acitretin, Adapalene, Afatinib, Afloqualone, Alitretinoin (Systemic), Alitretinoin (Topical), Aminolevulinic Acid (Systemic), Aminolevulinic Acid (Topical), Amiodarone, Bendroflumethiazide, Bexarotene (Systemic), Bexarotene (Topical), Bicalutamide, Calcitriol (Topical), Celecoxib, Chlorothiazide, ChlorproMAZINE, ChlorproPAMIDE, Chlorthalidone, Ciprofloxacin (Systemic), Cobimetinib, Cyclopenthiazide, Demeclocycline, Dexibuprofen, Dexketoprofen, Diclofenac (Systemic), Diclofenac (Topical), Diflunisal, Dipyrone, Dong Quai, Doxycycline, Etodolac, Etofenamate, Etoricoxib, Fenoprofen, Floctafenine, FluPHENAZine, Flurbiprofen (Systemic), Gemifloxacin, Gliclazide, Glimepiride, GlipiZIDE, GlyBURIDE, Griseofulvin, HydroCHLOROthiazide, Hydroflumethiazide, Ibuprofen, Ibuprofen (Topical), Indapamide, Indomethacin, ISOtretinoin (Systemic), Isotretinoin (Topical), Ketoprofen, Ketorolac (Nasal), Ketorolac (Systemic), LevoFLOXacin (Oral Inhalation), LevoFLOXacin (Systemic), Lomefloxacin, Lornoxicam, Loxoprofen, Lymecycline, Meclofenamate, Mefenamic Acid, Meloxicam, Methotrimeprazine, Methyclothiazide, MetOLazone, Minocycline, Morniflumate, Moxifloxacin (Systemic), Nabumetone, Nadifloxacin, Nalidixic Acid, Naproxen, Nimesulide, Norfloxacin, Ofloxacin (Systemic), Oxaprozin, Oxytetracycline, Panitumumab, Parecoxib, Pelubiprofen, Periciazine, Perphenazine, Phenylbutazone, Pipemidic Acid, Pipotiazine, Pirfenidone, Piroxicam (Systemic), Piroxicam (Topical), Porfimer, Prochlorperazine, Promazine, Propyphenazone, Simeprevir, Sparfloxacin, St John's Wort, SulfADIAZINE, Sulfadoxine, Sulfamethoxazole, SulfiSOXAZOLE, Sulindac, Talniflumate, Tenoxicam, Tetracycline (Systemic), Thioridazine, Tiaprofenic Acid, TOLAZamide, TOLBUTamide, Tolfenamic Acid, Tolmetin, Tretinoin (Systemic), Tretinoin (Topical), Trifluoperazine, Vemurafenib, Verteporfin, Voriconazole, Xipamide, Zaltoprofen</p>\n</div> \n<p><b>Discussion</b> The labeling for orally administered aminolevulinic acid states that photosensitizing agents should be avoided within 24 hours before or 24 hours after administration of oral aminolevulinic acid.<sup>1</sup> The labeling for topical aminolevulinic acid products caution that concurrent use with other photosensitizing agents may enhance the photosensitivity reaction.<sup>2,3,4</sup><br><br>One case report describes a patient taking St Johns wort who experienced a severe photosensivity reaction after treatment with aminolevulinic acid.<sup>5</sup> Australian labeling specifically recommends discontinuation of the photosensitizer St Johns wort 2 weeks prior to treatment with aminolevulinic acid.<sup>4</sup> The individual drugs listed herein as being photosensitizing agents are included primarily based on the findings of published analyses/reviews and individual drug labeling information.<sup>1,6,7,8</sup><br><br>The proposed mechanism for this potential interaction is additive phototoxicity between aminolevulinic acid and other photosensitizing agents.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gleolan (aminolevulinic acid) for oral solution [prescribing information]. Dessau-Rosslau, Germany: IDT Biologika GmbH; June 2017.</p>\n<p>2. Ameluz (aminolevulinic acid) gel [prescribing information]. Wakefield, MA: Biofrontera Inc; May 2016.</p>\n<p>3. Levulan (aminolevulinic acid) topical solution [prescribing information]. Wilmington, MA: DUSA Pharmaceuticals Inc; March 2010.</p>\n<p>4. Alacare (aminolevulinic acid) dermal patch [summary of product characteristics]. Warriewood, New South Wales, Australia: Link Medical Products; March 2015. </p>\n<p>5. Ladner DP, Klein SD, Steiner RA, Walt H. Synergistic toxicity of delta-aminolaevulinic acid-induced protoporphyrin IX used for photodiagnosis and hypericum extract, a herbal antidepressant. <i>Br J Dermatol</i>. 2001;144(4):916-918. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11298571\">[PubMed 11298571]</a></p>\n<p>6. Naldi L, Conforti A, Venegoni M, et al. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. <i>Br J Clin Pharmacol</i>. 1999;48(6):839-846. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10594488\">[PubMed 10594488]</a></p>\n<p>7. Lankerani L, Baron ED. Photosensitivity to exogenous agents. <i>J Cutan Med Surg</i>. 2004;8(6):424-431. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15988550\">[PubMed 15988550]</a></p>\n<p>8. Drucker AM, Rosen CF. Drug-induced photosensitivity: culprit drugs, management and prevention. <i>Drug Saf</i>. 2011;34(10):821-837. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21879777\">[PubMed 21879777]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11348":"<p><b>Title</b> Dexamethasone (Ophthalmic) / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dexamethasone (Ophthalmic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for signs and symptoms of corticosteroid excess (ie, Cushing syndrome) if ophthalmic dexamethasone is used in a patient on a strong CYP3A4 inhibitor.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> One case report describes a 51-year-old woman with HIV taking atazanavir/ritonavir (300 mg/100 mg once daily) who experienced weight gain, adrenal axis suppression, and avascular necrosis of the hip 8 months after initiation of dexamethasone eye drops (0.1% drops 6 times daily) and betamethasone ophthalmic ointment (0.1% applied nightly).<sup>1</sup> Serum concentrations of dexamethasone were detectable upon presentation (1.4 to 1.7 nmol/L). Her atazanavir/ritonavir was switched to efavirenz while her dexamethasone eye drops were continued. Over the subsequent year, her weight declined, her adrenal function improved, and her serum dexamethasone concentrations fell to undetectable levels.<sup>1</sup> Another case report describes a 15-year-old boy with HIV and vernal keratoconjunctivitis that was managed with darunavir/ritonavir (800 mg/100 mg once daily) and dexamethasone ophthalmic drops (0.1% drop twice daily).<sup>2</sup> After a corneal epithelial defect was identified, his dexamethasone dose was increased to 1 drop every hour.<sup>2</sup> After 2 weeks on this higher dose dexamethasone regimen he developed a moon-shaped face and after 6 weeks he had gained over 10 kg and had developed adrenal suppression.<sup>2</sup><br><br>The mechanism of this interaction is likely due to protease inhibitor (and other strong CYP3A4 inhibitors)-mediated inhibition of CYP3A4, an enzyme responsible for dexamethasone metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Molloy A, Matheson NJ, Meyer PA, Chaterjee K, Gkrania-Klotsas E. Cushing's syndrome and adrenal axis suppression in a patient treated with ritonavir and corticosteroid eye drops. <i>AIDS</i>. 2011;25(10):1337-1339. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21659797\">[PubMed 21659797]</a></p>\n<p>2. Rainsbury PG, Sharp J, Tappin A, Hussey M, Lenko A, Foster C. Ritonavir and topical ocular corticosteroid induced Cushing's syndrome in an adolescent with HIV-1 infection. <i>Pediatr Infect Dis J</i>. 2017;36(5):502-503. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28060049\">[PubMed 28060049]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11349":"<p><b>Title</b> Bacampicillin / Allopurinol</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Allopurinol may enhance the potential for allergic or hypersensitivity reactions to Bacampicillin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased incidence of skin rash (hypersensitivity reactions) during concomitant use of these agents.</p> \n<p><b>Discussion</b> Epidemiological data revealed an increased incidence of skin rash in patients taking ampicillin (the active moiety of the prodrug bacampicillin) plus allopurinol (22%) versus those taking ampicillin alone (7.5%).<sup>1,2</sup> Another report showed similar results for both ampicillin and amoxicillin.<sup>3</sup> It is unknnown whether this data demonstrates allopurinol potentiation of ampicillin/amoxicillin effects or simply reflects allopurinol-independent effects.</p> \n<p><b>Footnotes</b> </p>\n<p> 1. Excess of ampicillin rashes associated with allopurinol or hyperuricemia. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. <i>N Engl J Med</i>. 1972;286(10):505-507. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4258181\">[PubMed 4258181]</a></p>\n<p>2. Bergen T, Engeset A, Olszewski W, et al. Distribution to human peripheral lymph of amoxycillin and of ampicillin from the oral prodrug bacampicillin. <i>J Antimicrob Chemother</i>. 1983;12(5):497-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6671926\">[PubMed 6671926]</a></p>\n<p>3. Jick H, Porter JB. Potentiation of ampicillin skin reactions by allopurinol or hyperuricemia. <i>J Clin Pharmacol</i>. 1981;21(10):456-458. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6458626\">[PubMed 6458626]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11350":"<p><b>Title</b> Atenolol / Bacampicillin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Bacampicillin may decrease the bioavailability of Atenolol. <b>Severity</b> Moderate <b>Reliability Rating</b> Excellent </p> \n<p><b>Patient Management</b> Monitor for decreased therapeutic effects of atenolol if bacampicillin is initiated/dose increased, or increased effects if bacampicillin is discontinued/dose decreased.</p> \n<p><b>Discussion</b> The bioavailability of atenolol was reduced by approximately 50% in 6 normal subjects when coadministered with ampicillin (1 g oral) in both a single dose and multiple dose setting (6 days).<sup>1</sup> The reduction was slightly greater in the 6-day arm of the study. The pharmacodynamics of atenolol were reduced. In another study, the bioavailability of atenolol following a 1 g dose of ampicillin was approximately 3 times greater than when the atenolol was administered following ampicillin 250 mg 4 times/day (51% and 18%, respectively).<sup>2</sup> The mechanism of this interaction is unknown. The effect of other penicillins on atenolol or other beta-blockers is unknown. Bacampicillin is an oral prodrug of ampicillin.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Schafer-Korting M, Kirch W, Axthelm T, et al. Atenolol interaction with aspirin, allopurinol, and ampicillin. <i>Clin Pharmacol Ther</i>. 1983;33(3):283-288. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6825385\">[PubMed 6825385]</a></p>\n<p>2. McLean AJ, Tonkin A, McCarthy P, et al. Dose-dependence of atenolol-ampicillin interaction. <i>Br J Clin Pharmacol</i>. 1984;18(6):969-971. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6529538\">[PubMed 6529538]</a></p>\n<p>3. Bergen T, Engeset A, Olszewski W, et al. Distribution to human peripheral lymph of amoxycillin and of ampicillin from the oral prodrug bacampicillin. <i>J Antimicrob Chemother</i>. 1983;12(5):497-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6671926\">[PubMed 6671926]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11351":"<p><b>Title</b> Bacampicillin / Chloroquine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Chloroquine may decrease the serum concentration of Bacampicillin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Chloroquine prescribing information recommends separating administration of ampicillin (the active moiety of the prodrug bacampicillin) and chloroquine by at least 2 hours to minimize any potential negative impact of chloroquine on ampicillin bioavailability.</p> \n<p><b>Discussion</b> Based on data showing that the amount of ampicillin (the active moiety of the prodrug bacampicillin) excreted in the urine was decreased with coadministered chloroquine (19% vs. 29% of dose excreted over 8 hrs; n=7), it was hypothesized that chloroquine may decrease ampicillin bioavailability.<sup>1,2,3</sup> The clinical significance of this interaction is uncertain, but despite this seemingly modest effect, chloroquine prescribing information recommends separating administration of ampicillin and chloroquine by at least 2 hours to minimize any potential negative impact of chloroquine on ampicillin bioavailability.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bergen T, Engeset A, Olszewski W, et al. Distribution to human peripheral lymph of amoxycillin and of ampicillin from the oral prodrug bacampicillin. <i>J Antimicrob Chemother</i>. 1983;12(5):497-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6671926\">[PubMed 6671926]</a></p>\n<p>2. Ali HM. Reduced ampicillin bioavailability following oral coadministration with chloroquine. <i>J Antimicrob Chemother</i>. 1985;15(6):781-784. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=4030540\">[PubMed 4030540]</a></p>\n<p>3. Aralen (chloroquine) [prescribing information]. Bridgewater, NJ: sanofi-aventis U.S. LLC; September 2008.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11352":"<p><b>Title</b> Bacampicillin / Lanthanum</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Lanthanum may decrease the serum concentration of Bacampicillin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Administer bacampicillin at least 2 hours before or after lanthanum.</p> \n<p><b>Discussion</b> Per lanthanum prescribing information, compounds such as ampicillin that may bind to cationic antacids should not be administered within 2 hours of lanthanum due to a risk of adsorption in the gastrointestinal tract.<sup>1</sup> Bacampicillin is an oral prodrug of ampicillin.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Fosrenol (lanthanum carbonate) [prescribing information]. Wayne, PA: Shire US Inc; April 2011.</p>\n<p>2. Bergen T, Engeset A, Olszewski W, et al. Distribution to human peripheral lymph of amoxycillin and of ampicillin from the oral prodrug bacampicillin. <i>J Antimicrob Chemother</i>. 1983;12(5):497-502. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6671926\">[PubMed 6671926]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11353":"<p><b>Title</b> Disulfiram / Bacampicillin</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Bacampicillin may enhance the adverse/toxic effect of Disulfiram. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Avoid the concomitant use of bacampicillin and disulfiram.</p> \n<p><b>Discussion</b> The bacampicillin product labeling states that the coadministration of bacampicillin and disulfiram should be avoided.<sup>1</sup> There are no existing reports of a possible bacampicillin-disulfiram interaction published in the English language and the reason for this recommendation is unknown/unclear.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bachem (bacampicillin) tablet [KR prescribing information]. http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=198400054. Accessed March 15, 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11354":"<p><b>Title</b> Vitamin K Antagonists / Isoconazole</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Isoconazole may increase the serum concentration of Vitamin K Antagonists. <b>Severity</b> Minor <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> No action required.</p>\n<div>\n <p><b>Vitamin K Antagonists Interacting Members</b> Acenocoumarol, Phenindione, Warfarin</p>\n</div> \n<p><b>Discussion</b> No studies have evaluated the effect of vaginal isoconazole on the pharmacokinetics of vitamin K antagonists and no cases of a potential interaction between these agents have been reported. However, isoconazole product labeling warns that treatment with isoconazole may increase concentrations of vitamin K antagonists.<sup>1</sup> The reason for this warning is unclear, but increases in vitamin K antagonist effects have been reported with vaginal miconazole.<sup>2,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Gyno-Travogen (isoconazole nitrate) [SG summary of product characteristics]. Ojo de Agua Ixtaczoquitlan, Orizaba, Ver., Mexico: Bayer de Mexico, S.A. de C.V.; December 2016.</p>\n<p>2. Murty M. Miconazole-warfarin interaction: increased INR. <i>CMAJ</i>. 2001;165(1):81-82, 85-86. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11468962\">[PubMed 11468962]</a></p>\n<p>3. Thirion DJ, Zanetti LA. Potentiation of warfarin's hypoprothrombinemic effect with miconazole vaginal suppositories. <i>Pharmacotherapy</i>. 2000;20(1):98-99. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10641982\">[PubMed 10641982]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11355":"<p><b>Title</b> Tacrolimus (Systemic) / Ledipasvir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ledipasvir may decrease the serum concentration of Tacrolimus (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased tacrolimus serum concentrations and effects if combined with ledipasvir. Tacrolimus dose increases may be required.</p> \n<p><b>Discussion</b> In a clinical study, 11 renal transplant recipients taking tacrolimus initiated treatment with sofosbuvir/ledipasvir for hepatitis C virus (HCV) infection.<sup>1</sup> The mean tacrolimus concentration-to-dose ratio decreased 31% over the course of treatment and 6 patients (55%) required a tacrolimus dose increase.<sup>1</sup> In a retrospective study of 6 kidney transplant recipients treated with tacrolimus who received 12 weeks of treatment with sofosbuvir/ledipasvir, tacrolimus concentrations decreased 27% despite tacrolimus dose adjustments during therapy.<sup>2</sup> In 2 retrospective studies (N = 164) of kidney transplant patients receiving tacrolimus, treatment of HCV infection with a direct-acting antiviral agent (approximately 60% of patients received ledipasvir/sofosbuvir) decreased tacrolimus serum concentrations 21% to 25% over the course of treatment.<sup>3,4</sup> Tacrolimus doses were numerically higher at the end of HCV treatment compared with baseline tacrolimus doses.<sup>3,4</sup><br><br>In contrast, other reports describe 6 liver transplant recipients taking tacrolimus who had no change in their tacrolimus serum concentration after treatment with sofosbuvir/ledipasvir.<sup>5,6</sup><br><br>The mechanism of this potential interaction is unknown. It is unclear if the reduced tacrolimus exposure seen in these studies is the result of a true drug interaction or merely an improvement in liver function and changes in cytokine levels, as a result of treating HCV, leading to increased tacrolimus metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Eisenberger U, Guberina H, Willuweit K, et al. Successful treatment of chronic hepatitis C virus infection with sofosbuvir and ledipasvir in renal transplant recipients. <i>Transplantation</i>. 2017;101(5):980-986. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27495770\">[PubMed 27495770]</a></p>\n<p>2. Sawinski D, Lee DH, Doyle AM, Blumberg EA. Successful posttransplant treatment of hepatitis C with ledipasvir-sofosbuvir in HIV positive kidney transplant recipients. <i>Transplantation</i>. 2017;101(5):974-979. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27467534\">[PubMed 27467534]</a></p>\n<p>3. Gentil MA, Gonzalez-Corvillo C, Perello M, et al. Hepatitis C treatment with direct-acting antivirals in kidney transplant: preliminary results from a multicenter study. <i>Transplant Proc</i>. 2016;48(9):2944-2946. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27932113\">[PubMed 27932113]</a></p>\n<p>4. Suarez Benjumea A, Gonzalez-Corvillo C, Sousa JM, et al. Hepatitis C virus in kidney transplant recipients: a problem on the path to eradication. <i>Transplant Proc</i>. 2016;48(9):2938-2940. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27932111\">[PubMed 27932111]</a></p>\n<p>5. Oya Y, Sugawara Y, Watanabe T, et al. Ledipasvir and sofosbuvir for recurrent hepatitis C after liver transplantation. <i>Biosci Trends</i>. 2017;10(6):496-499. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27990005\">[PubMed 27990005]</a></p>\n<p>6. Kawaoka T, Imamura M, Morio K, et al. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation. <i>Clin J Gastroenterol</i>. 2017;10(2):179-184. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28224470\">[PubMed 28224470]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11356":"<p><b>Title</b> Betrixaban / P-glycoprotein/ABCB1 Inhibitors</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Betrixaban. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Decrease the betrixaban dose to an initial single dose of 80 mg followed by 40 mg once daily if combined with a P-glycoprotein inhibitor.</p>\n<div>\n <p><b>P-glycoprotein/ABCB1 Inhibitors Interacting Members</b> Amiodarone, Azithromycin (Systemic), Carvedilol, Clarithromycin, CycloSPORINE (Systemic), Daclatasvir, Dronedarone, Eliglustat, Erythromycin (Systemic), Flibanserin, Glecaprevir and Pibrentasvir, Itraconazole, Ivacaftor, Ketoconazole (Systemic), Lapatinib, Ledipasvir, Neratinib, Ombitasvir, Paritaprevir, and Ritonavir, Propafenone, QuiNIDine, QuiNINE, Ranolazine, Ritonavir, Rolapitant, Simeprevir, Telaprevir, Velpatasvir, Vemurafenib, Verapamil</p>\n</div> \n<p><b>Discussion</b> In pharmacokinetic studies described in the betrixaban prescribing information, coadministration with ketoconazole increased the betrixaban AUC and maximum serum concentration (Cmax) approximately 2-fold and 2.5-fold, respectively, and coadministration with verapamil increased the betrixaban AUC and Cmax approximately 3-fold and 5-fold, respectively.<sup>1</sup><br><br>Betrixaban prescribing information recommends a betrixaban dose reduction to an initial single dose of 80 mg followed by 40 mg once daily in patients taking P-glycoprotein (P-gp) inhibitors.<sup>1</sup><br><br>Betrixaban undergoes negligible CYP metabolism, so the mechanism of these interactions is likely due to ketoconazole and verapamil-mediated inhibition of P-gp, a transporter responsible for betrixaban disposition.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Bevyxxa (betrixaban) [prescribing information]. South San Francisco, CA: Portola Pharmaceuticals Inc; June 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11357":"<p><b>Title</b> CycloSPORINE (Systemic) / Ledipasvir</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> Ledipasvir may increase the serum concentration of CycloSPORINE (Systemic). <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> Although ledipasvir can inhibit P-glycoprotein (P-gp) and cyclosporine is a known substrate of P-gp, the interaction between these agents appears negligible. One report describes 2 liver transplant recipients taking cyclosporine (50 mg daily) who received sofosbuvir/ledipasvir (400 mg/90 mg daily) for 12 weeks.<sup>1</sup> Cyclosporine trough concentrations remained stable throughout sofosbuvir/ledipasvir therapy and no cyclosporine dose adjustments were required.<sup>1</sup> Another report describes a kidney transplant recipient taking cyclosporine (100 mg twice daily) who received sofosbuvir/ledipasvir for 12 weeks.<sup>2</sup> His cyclosporine trough concentration was only reported at baseline and 3 weeks after sofosbuvir/ledipasvir initiation, but only rose 16% (95 ng/mL to 110 ng/mL) and no cyclosporine dose adjustment was required.<sup>2</sup><br><br>Prescribing information for sofosbuvir/ledipasvir states that ledipasvir has no clinically relevant effect on cyclosporine concentrations.<sup>3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Kawaoka T, Imamura M, Morio K, et al. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation. <i>Clin J Gastroenterol</i>. 2017;10(2):179-184. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28224470\">[PubMed 28224470]</a></p>\n<p>2. Jha R, Fatima R, Lakhtakia S, Jha A, Srikant P, Narayan G. Ledipasvir and sofosbuvir for treatment of post-renal transplant hepatitis C infection: a case report with review of literature. <i>Indian J Nephrol</i>. 2016;26(3):216-219. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27194839\">[PubMed 27194839]</a></p>\n<p>3. Harvoni (sofosbuvir and ledipasvir) [prescribing information]. Foster City, CA: Gilead Sciences Inc; April 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11358":"<p><b>Title</b> Tacrolimus (Systemic) / Daclatasvir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Daclatasvir may decrease the serum concentration of Tacrolimus (Systemic). Specifically, this decrease in tacrolimus concentrations may occur with continued prolonged combination therapy. Daclatasvir may increase the serum concentration of Tacrolimus (Systemic). Specifically, this increase in tacrolimus concentrations may occur during the first week of combined therapy. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor tacrolimus serum concentrations closely if combined with daclatasvir. Tacrolimus concentrations may initially be elevated, but then may decrease significantly. Tacrolimus dose increases may be required.</p> \n<p><b>Discussion</b> In a retrospective study of 6 liver transplant recipients treated with tacrolimus, treatment with daclatasvir (60 mg once daily) and asunaprevir (100 mg twice daily) for 24 weeks reduced tacrolimus serum concentrations 32%, but no tacrolimus dose adjustments were required to maintain therapeutic serum concentrations.<sup>1</sup> In another retrospective analysis of 10 liver transplant recipients treated with tacrolimus, treatment with daclatasvir/asunaprevir initially increased the tacrolimus concentration-to-dose ratio 32% in the first week, but then it decreased 25% from baseline by week 2 and remained decreased throughout daclatasvir therapy.<sup>2</sup> In 2 retrospective studies (N = 164) of kidney transplant patients receiving tacrolimus, treatment of hepatitis C virus (HCV) infection with a direct-acting antiviral agent (approximately 18% of patients received daclatasvir/sofosbuvir) decreased tacrolimus serum concentrations 21% to 25% over the course of treatment.<sup>3,4</sup> Tacrolimus doses were numerically higher at the end of HCV treatment compared with baseline tacrolimus doses.<sup>3,4</sup> Case reports describe tacrolimus-treated patients who initially had increases in tacrolimus concentrations after initiation of daclatasvir/asunaprevir,<sup>5</sup> but ultimately had significant decreases in tacrolimus serum concentrations (70%)<sup>6,7</sup> and required increases in tacrolimus dose (33% to 50%).<sup>5,6,7</sup><br><br>In contrast, a pharmacokinetic study of healthy volunteers found that daclatasvir (60 mg daily x 8 days) had no effect on the pharmacokinetics of tacrolimus (5 mg single dose).<sup>8</sup> Additionally, other case reports describe patients taking tacrolimus who did not have changes in their tacrolimus concentrations with the addition of daclatasvir to their treatment regimens.<sup>7,9,10,11</sup><br><br>The mechanism of this potential interaction has not been fully investigated. Initial increases in tacrolimus concentrations seen in some analyses may be due to daclatasvir/asunaprevir-mediated inhibition of P-glycoprotein, a transporter responsible for tacrolimus disposition. The mechanism behind the reduced tacrolimus exposure seen with continued combination therapy in these studies may not be the result of a true drug interaction, but merely an improvement in liver function and changes in cytokine levels, as a result of treating HCV, leading to increased tacrolimus metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Honda M, Sugawara Y, Watanabe T, et al. Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation [published online December 21, 2016]. <i>Hepatol Res</i>. doi: 10.1111/hepr.12853. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28002876\">[PubMed 28002876]</a></p>\n<p>2. Ueda Y, Uemoto S. Decreased tacrolimus concentration following a temporal increase during interferon-free therapy with asunaprevir and daclatasvir in patients with recurrent hepatitis C after liver transplantation. <i>Transpl Int</i>. 2016;29(1):119-121. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26270021\">[PubMed 26270021]</a></p>\n<p>3. Gentil MA, Gonzalez-Corvillo C, Perello M, et al. Hepatitis C treatment with direct-acting antivirals in kidney transplant: preliminary results from a multicenter study. <i>Transplant Proc</i>. 2016;48(9):2944-2946. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27932113\">[PubMed 27932113]</a></p>\n<p>4. Suarez Benjumea A, Gonzalez-Corvillo C, Sousa JM, et al. Hepatitis C virus in kidney transplant recipients: a problem on the path to eradication. <i>Transplant Proc</i>. 2016;48(9):2938-2940. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27932111\">[PubMed 27932111]</a></p>\n<p>5. Ueda Y, Kaido T, Hatano E, Ohtsuru S, Uemoto S. Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C. <i>Hepatol Res</i>. 2015;45(13):1360-1362. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25704315\">[PubMed 25704315]</a></p>\n<p>6. Smolders EJ, Pape S, de Kanter CT, van den Berg AP, Drenth JP, Burger DM. Decreased tacrolimus plasma concentrations during HCV therapy: a drug-drug interaction or is there an alternative explanation? <i>Int J Antimicrob Agents</i>. 2017;49(3):379-382. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28185946\">[PubMed 28185946]</a></p>\n<p>7. Kawaoka T, Imamura M, Morio K, et al. Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: case report. <i>Hepatol Res</i>. 2016;46(7):707-712. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26439054\">[PubMed 26439054]</a></p>\n<p>8. Bifano M, Adamczyk R, Hwang C, Kandoussi H, Marion A, Bertz RJ. An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects. <i>Clin Drug Investig</i>. 2015;35(5):281-289. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25896946\">[PubMed 25896946]</a></p>\n<p>9. Fontana RJ, Hughes EA, Bifano M, et al. Sofosbuvir and daclatasvir combination therapy in a liver transplant recipient with severe recurrent cholestatic hepatitis C. <i>Am J Transplant</i>. 2013;13(6):1601-1605. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23593993\">[PubMed 23593993]</a></p>\n<p>10. Seifert LL, Heinzow H, Kabar I, Christensen S, Husing A, Schmidt HH. Successful anti-HCV therapy of a former intravenous drug user with sofosbuvir and daclatasvir in a peritransplant setting: a case report. <i>Am J Case Rep</i>. 2016;17:605-610. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=27554644\">[PubMed 27554644]</a></p>\n<p>11. Koshino K, Ushigome H, Masuda K, et al. Effective treatment with daclatasvir and asunaprevir in kidney transplant patients infected with hepatitis C virus: a report of two cases. <i>Transplant Proc</i>. 2017;49(5):1053-1055. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28583525\">[PubMed 28583525]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11359":"<p><b>Title</b> Tacrolimus (Systemic) / Asunaprevir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Asunaprevir may increase the serum concentration of Tacrolimus (Systemic). Specifically, this increase in tacrolimus concentrations may occur during the first week of combined therapy. Asunaprevir may decrease the serum concentration of Tacrolimus (Systemic). Specifically, this decrease in tacrolimus concentrations may occur with continued prolonged combination therapy. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor tacrolimus serum concentrations closely if combined with asunaprevir. Tacrolimus concentrations may initially be elevated, but then may decrease significantly. Tacrolimus dose increases may be required.</p> \n<p><b>Discussion</b> In a retrospective study of 6 liver transplant recipients treated with tacrolimus, treatment with daclatasvir (60 mg once daily) and asunaprevir (100 mg twice daily) for 24 weeks reduced tacrolimus serum concentrations 32%, but no tacrolimus dose adjustments were required to maintain therapeutic serum concentrations.<sup>1</sup> In another retrospective analysis of 10 liver transplant recipients on tacrolimus, treatment with daclatasvir/asunaprevir initially increased the tacrolimus concentration-to-dose ratio 32% in the first week, but then it decreased 25% from baseline by week 2 and remained decreased throughout daclatasvir therapy.<sup>2</sup> Case reports describe tacrolimus-treated patients who initially had increases in tacrolimus concentrations after initiation of daclatasvir/asunaprevir,<sup>3</sup> but ultimately had significant decreases in tacrolimus serum concentrations (69%)<sup>4</sup> and required increases in tacrolimus dose (33%).<sup>3,4</sup><br><br>In contrast, other case reports describe patients taking tacrolimus who did not have changes in their tacrolimus concentrations with the addition of asunaprevir to their treatment regimens.<sup>4,5</sup><br><br>The mechanism of this potential interaction has not been fully investigated. Initial increases in tacrolimus concentrations seen in some analyses may be due to daclatasvir/asunaprevir-mediated inhibition of P-glycoprotein, a transporter responsible for tacrolimus disposition. The mechanism behind the reduced tacrolimus exposure seen with continued combination therapy in these studies may not be the result of a true drug interaction, but merely an improvement in liver function and changes in cytokine levels, as a result of treating hepatitis C virus infection, leading to increased tacrolimus metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Honda M, Sugawara Y, Watanabe T, et al. Outcomes of treatment with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation [published online December 21, 2016]. <i>Hepatol Res</i>. doi: 10.1111/hepr.12853. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28002876\">[PubMed 28002876]</a></p>\n<p>2. Ueda Y, Uemoto S. Decreased tacrolimus concentration following a temporal increase during interferon-free therapy with asunaprevir and daclatasvir in patients with recurrent hepatitis C after liver transplantation. <i>Transpl Int</i>. 2016;29(1):119-121. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26270021\">[PubMed 26270021]</a></p>\n<p>3. Ueda Y, Kaido T, Hatano E, Ohtsuru S, Uemoto S. Safe and effective treatment with daclatasvir and asunaprevir in a liver transplant recipient with severe cholestatic hepatitis C. <i>Hepatol Res</i>. 2015;45(13):1360-1362. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25704315\">[PubMed 25704315]</a></p>\n<p>4. Kawaoka T, Imamura M, Morio K, et al. Three patients treated with daclatasvir and asunaprevir for recurrent hepatitis C after liver transplantation: case report. <i>Hepatol Res</i>. 2016;46(7):707-712. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26439054\">[PubMed 26439054]</a></p>\n<p>5. Koshino K, Ushigome H, Masuda K, et al. Effective treatment with daclatasvir and asunaprevir in kidney transplant patients infected with hepatitis C virus: a report of two cases. <i>Transplant Proc</i>. 2017;49(5):1053-1055. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=28583525\">[PubMed 28583525]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11360":"<p><b>Title</b> Daclatasvir / CycloSPORINE (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> B: No action needed</p> \n<p><b>Summary</b> CycloSPORINE (Systemic) may increase the serum concentration of Daclatasvir. <b>Severity</b> Minor <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> No action required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 14 healthy volunteers, coadministration of daclatasvir (60 mg daily x 8 days) and cyclosporine (400 mg single dose on day 6) increased the daclatasvir AUC and minimum serum concentration 40% and 56%, respectively.<sup>1</sup> Daclatasvir had no effect on the cyclosporine AUC or maximum serum concentration.<sup>1</sup> A single case report also describes a liver transplant recipient taking cyclosporine who experienced no change in cyclosporine trough concentrations with daclatasvir treatment.<sup>2</sup><br><br>The daclatasvir prescribing information states that daclatasvir has no clinically relevant effect on cyclosporine exposure and that the changes in daclatasvir exposure seen with cyclosporine coadministration are not clinically significant.<sup>3</sup><br><br>The mechanism of this potential interaction has not been fully investigated, but cyclosporine-mediated inhibition of CYP3A4, an enzyme responsible for daclatasvir metabolism, likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Bifano M, Adamczyk R, Hwang C, Kandoussi H, Marion A, Bertz RJ. An open-label investigation into drug-drug interactions between multiple doses of daclatasvir and single-dose cyclosporine or tacrolimus in healthy subjects. <i>Clin Drug Investig</i>. 2015;35(5):281-289. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25896946\">[PubMed 25896946]</a></p>\n<p>2. Fontana RJ, Hughes EA, Appelman H, Hindes R, Dimitrova D, Bifano M. Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. <i>Liver Transpl</i>. 2012;18(9):1053-1059. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22706796\">[PubMed 22706796]</a></p>\n<p>3. Daklinza (daclatasvir) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; February 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11361":"<p><b>Title</b> Fluvastatin / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Fluvastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for signs and symptoms of fluvastatin toxicity (eg, myalgia, rhabdomyolysis, liver function test abnormalities) during concomitant treatment with cobicistat and cobicistat-containing products.</p> \n<p><b>Discussion</b> US prescribing information for some cobicistat-containing products recommends initiation of concomitant fluvastatin at the lowest recommended dose and careful titration while monitoring for fluvastatin safety.<sup>1,2</sup> No specific pharmacokinetic data are reported. The specific mechanism for this potential interaction is unclear, but cobicistat inhibition of fluvastatin transport via SLCO1B1 (ie, OATP1B1), SLO1B3 (ie, OAT1B3) and/or BCRP inhibition may contribute.<sup>3,4,5</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prezcobix (darunavir and cobicistat) [prescribing information]. Titusville, NJ: Janssen Therapeutics, Division of Janssen Products, LP; June 2017.</p>\n<p>2. Evotaz (atazanavir and cobicistat) [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Company; January 2017.</p>\n<p>3. Chauvin B, Drouot S, Barrail-Tran A, et al. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. <i>Clin Pharmacokinet</i>. 2013;52(10):815-831. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23703578\">[PubMed 23703578]</a></p>\n<p>4. Niemi M, Pasanen MK, Neuvonen PJ. Organic anion transporting polypeptide 1B1: a genetically polymorphic trasnsporter of major importance for hepatic drug update. <i>Pharmacol Rev</i>. 2011;63(1):157-181. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=21245207\">[PubMed 21245207]</a></p>\n<p>5. Kopplow K, Letschert K, Konig J, et al. Human hepatobiliary transport of organic anions analyzed by quadruple-transfected cells. <i>Mol Pharmacol</i>. 2005;68(4):1031-1038. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16046661\">[PubMed 16046661]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11362":"<p><b>Title</b> Pitavastatin / Cobicistat</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cobicistat may increase the serum concentration of Pitavastatin. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for signs and symptoms of pitavastatin toxicity (eg, myalgia, rhabdomyolysis, liver function test abnormalities) during concomitant treatment with cobicistat and cobicistat-containing products.</p> \n<p><b>Discussion</b> US prescribing information for darunavir/cobicistat recommends initiation of concomitant pitavastatin at the lowest recommended dose and careful titration while monitoring for pitavastatin safety.<sup>1</sup> No specific pharmacokinetic data are reported. The specific mechanism for this potential interaction is unclear, but cobicistat inhibition of pitavastatin transport via SLCO1B1 (ie, OATP1B1) may contribute.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Prezcobix (darunavir and cobicistat) [prescribing information]. Titusville, NJ: Janssen Therapeutics Division of Janssen Products LP; June 2017.</p>\n<p>2. Chauvin B, Drouot S, Barrail-Tran A, et al. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors. <i>Clin Pharmacokinet</i>. 2013;52(10):815-831. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=23703578\">[PubMed 23703578]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11366":"<p><b>Title</b> SUFentanil / CYP3A4 Inducers (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> CYP3A4 Inducers (Strong) may decrease the serum concentration of SUFentanil. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> If a strong CYP3A4 inducer is initiated in a patient on sufentanil, monitor for decreased sufentanil effects and opioid withdrawal symptoms. Increases in sufentanil dose may be required. <br><br>If a strong CYP3A4 inducer is discontinued in a patient on sufentanil, monitor for increased sufentanil effects and toxicities (eg, respiratory depression). Decreases in sufentanil dose may be required.</p>\n<div>\n <p><b>CYP3A4 Inducers (Strong) Interacting Members</b> Apalutamide, CarBAMazepine, Enzalutamide, Fosphenytoin, Lumacaftor, Mitotane, PHENobarbital, Phenytoin, Primidone, RifAMPin</p>\n</div> \n<p><b>Discussion</b> No studies describe the effects of strong CYP3A4 inducers on sufentanil exposure, but in vitro data suggest that sufentanil is primarily metabolized by CYP3A4.<sup>1</sup> Sufentanil prescribing information states that CYP3A4 inducers may decrease plasma concentrations of sufentanil, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to sufentanil.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. <i>Anesth Analg</i>. 1996;82(1):167-172. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8712396\">[PubMed 8712396]</a></p>\n<p>2. Sufentanil [prescribing information]. Lake Forest, IL: Akorn Inc; December 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11367":"<p><b>Title</b> SUFentanil / CYP3A4 Inhibitors (Strong)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP3A4 Inhibitors (Strong) may increase the serum concentration of SUFentanil. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> If a strong CYP3A4 inhibitor is initiated in a patient on sufentanil, consider a sufentanil dose reduction and monitor for increased sufentanil effects and toxicities (eg, respiratory depression).<br><br>If a strong CYP3A4 inhibitor is discontinued in a patient on sufentanil, monitor for decreased sufentanil effects and opioid withdrawal symptoms. Increases in sufentanil dose may be required.</p>\n<div>\n <p><b>CYP3A4 Inhibitors (Strong) Interacting Members</b> Atazanavir, Boceprevir, Clarithromycin, Cobicistat, Darunavir, Idelalisib, Indinavir, Itraconazole, Ketoconazole (Systemic), Lopinavir, MiFEPRIStone, Nefazodone, Nelfinavir, Ombitasvir, Paritaprevir, and Ritonavir, Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir, Posaconazole, Ritonavir, Saquinavir, Telaprevir, Telithromycin, Voriconazole</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in sufentanil product labeling, the strong CYP3A4 inhibitor ketoconazole increased the sufentanil maximum serum concentration and AUC 19% and 77%, respectively.<sup>1</sup> Sufentanil prescribing information states that CYP3A4 inhibitors can increase plasma concentrations of sufentanil, resulting in increased or prolonged opioid effects, particularly when an inhibitor is added after a stable dose of sufentanil is achieved.<sup>1,2</sup><br><br>The mechanism of this interaction is likely ketoconazole-mediated inhibition of CYP3A4, an enzyme responsible for sufentanil metabolism.<sup>1,3</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Zalviso (sufentanil) sublingual tablets [summary of product characteristics]. Aachen, Germany: Grunenthal GmbH; March 2016.</p>\n<p>2. Sufentanil [prescribing information]. Lake Forest, IL: Akorn Inc; December 2016.</p>\n<p>3. Tateishi T, Krivoruk Y, Ueng YF, Wood AJ, Guengerich FP, Wood M. Identification of human liver cytochrome P-450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. <i>Anesth Analg</i>. 1996;82(1):167-172. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8712396\">[PubMed 8712396]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11368":"<p><b>Title</b> Monoamine Oxidase Inhibitors / SUFentanil</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> SUFentanil may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Specifically, the risk for serotonin syndrome or opioid toxicities (eg, respiratory depression, coma) may be increased. <b>Severity</b> Major <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Sufentanil should not be used with monoamine oxidase (MAO) inhibitors (or within 14 days of stopping an MAO inhibitor) due to the potential for serotonin syndrome and/or excessive CNS depression.</p>\n<div>\n <p><b>Monoamine Oxidase Inhibitors Interacting Members</b> Isocarboxazid, Linezolid, Methylene Blue, Moclobemide, Phenelzine, Procarbazine, Rasagiline, Safinamide, Selegiline, Syrian Rue, Tedizolid, Tranylcypromine</p>\n</div> \n<p><b>Discussion</b> The prescribing information for sufentanil states that sufentanil should not be used with monoamine oxidase (MAO) inhibitors (or within 14 days of stopping an MAO inhibitor) due to the potential for serotonin syndrome and opioid toxicity (eg, respiratory depression, coma).<sup>1</sup> Although no reports of toxicities have been reported with the use of sufentanil and MAO inhibitors, interactions between other opioids and MAO inhibitors have been documented.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Sufentanil [prescribing information]. Lake Forest, IL: Akorn Inc; December 2016.</p>\n<p>2. US Food and Drug Administration. FDA Drug Safety Communication: FDA warns about several safety issues with opioid pain medicines; requires label changes. Http://www.fda.gov/Drugs/DrugSafety/ucm489676.htm. Published March 22, 2016. Accessed August 29, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11369":"<p><b>Title</b> TiZANidine / Ciprofloxacin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ciprofloxacin (Systemic) may increase the serum concentration of TiZANidine. <b>Severity</b> Major <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Avoid concomitant use of tizanidine and ciprofloxacin. US prescribing information states that combined use is contraindicated.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 10 healthy volunteers, the AUC and maximum serum concentration (Cmax) of tizanidine (4 mg single dose) increased 10-fold and 7-fold, respectively, when administered after a 3-day course of ciprofloxacin (500 mg twice daily).<sup>1</sup> Two published case reports describe patients on stable tizanidine doses who experienced hypotension, drowsiness, and dizziness after initiation of ciprofloxacin.<sup>2,3</sup> Additionally, in a retrospective chart review, 3 of 8 patients who received concomitant ciprofloxacin and tizanidine experienced documented adverse events (eg, bradycardia, hypotension, drowsiness, confusion).<sup>2</sup><br><br>Tizanidine and ciprofloxacin prescribing information state that because ciprofloxacin can increase tizanidine concentrations and effects, combined use is contraindicated.<sup>4,5</sup><br><br>The suspected primary mechanism of this interaction is inhibition of CYP1A2-mediated tizanidine metabolism by ciprofloxacin.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. <i>Clin Pharmacol Ther</i>. 2004;76(6):598-606. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15592331\">[PubMed 15592331]</a></p>\n<p>2. Momo K, Homma M, Kohda Y, Ohkoshi N, Yoshizawa T, Tamaoka A. Drug interaction of tizanidine and ciprofloxacin: case report. <i>Clin Pharmacol Ther</i>. 2006;80(6):717-719. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=17178273\">[PubMed 17178273]</a></p>\n<p>3. Abd-Elsayed A, Elsharkawy H, Sakr W. A severe interaction between tizanidine and ciprofloxacin. <i>J Clin Anesth</i>. 2015;27(8):698. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26138629\">[PubMed 26138629]</a></p>\n<p>4. Zanaflex (tizanidine) [prescribing information]. Ardsley, NY: Aorda Therapeutics Inc; November 2013.</p>\n<p>5. Cipro (ciprofloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; July 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11370":"<p><b>Title</b> Bendamustine / Ciprofloxacin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ciprofloxacin (Systemic) may increase the serum concentration of Bendamustine. Concentrations of the active metabolites of bendamustine may be decreased. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Use caution when combining bendamustine with ciprofloxacin as exposure to both bendamustine and its active metabolites may be altered. The clinical consequence of this is unclear.</p> \n<p><b>Discussion</b> Metabolism of bendamustine to two active metabolites, gamma-hydroxy bendamustine and N-desmethyl-bendamustine, is mediated by the enzyme CYP1A2.<sup>1</sup> Inhibitors of CYP1A2, such as ciprofloxacin, would be expected to increase exposure to bendamustine and decrease exposure to both active metabolites. The clinical consequences of such a combination are unclear, but according to the bendamustine prescribing information, caution is warranted when using such combinations.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Treanda (bendamustine) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; February 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11371":"<p><b>Title</b> Pentoxifylline / Ciprofloxacin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ciprofloxacin (Systemic) may increase the serum concentration of Pentoxifylline. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased pentoxifylline effects/toxicities if combined with ciprofloxacin.</p> \n<p><b>Discussion</b> In a clinical study of 8 healthy volunteers, ciprofloxacin (750 mg single oral dose) increased the AUC of pentoxifylline (300 mg single intravenous dose administered over 1 hour) and the R and S isomers of its active M1 metabolite by 31%, 48%, and 36%, respectively.<sup>1</sup> <br><br>The suspected primary mechanism of this interaction is ciprofloxacin inhibition of CYP1A2-mediated pentoxifylline metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Magnusson M, Bergstrand IC, Bjorkman S, Heijl A, Roth B, Hoglund P. A placebo-controlled study of retinal blood flow changes by pentoxifylline and metabolites in humans. <i>Br J Clin Pharmacol</i>. 2006;61(2):138-147. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16433868\">[PubMed 16433868]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11372":"<p><b>Title</b> Pomalidomide / Ciprofloxacin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Ciprofloxacin (Systemic) may increase the serum concentration of Pomalidomide. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of pomalidomide and ciprofloxacin when possible. If coadministration is considered necessary, consider reducing the pomalidomide dose 50% and monitoring patients for increased pomalidomide effects/toxicities.</p> \n<p><b>Discussion</b> In a clinical study summarized in the pomalidomide US prescribing information, fluvoxamine (a strong CYP1A2 inhibitor) increased the pomalidomide AUC 2.25-fold and the combination of fluvoxamine and ketoconazole (a strong CYP3A4 inhibitor and P-glycoprotein inhibitor) increased the pomalidomide AUC 2.5-fold in 12 healthy volunteers.<sup>1,2</sup> Ketoconazole coadministration alone only increased the pomalidomide AUC 1.2-fold in a study of 16 healthy volunteers.<sup>1,2</sup> <br><br>Based on these findings, inhibition of CYP1A2 is the primary mechanism for increased pomalidomide exposure seen in these studies.<sup>1,2</sup> Pomalidomide prescribing information states that concomitant use of pomalidomide and strong CYP1A2 inhibitors should be avoided if possible. If combined use is necessary, the pomalidomide dose should be reduced 50%.<sup>1</sup> Although ciprofloxacin is listed as an example of a strong CYP1A2 inhibitor in pomalidomide labeling, only one study suggests ciprofloxacin is a strong CYP1A2 inhibitor.<sup>3</sup> Numerous other studies suggest ciprofloxacin is a moderate CYP1A2 inhibitor.<sup>4,5,6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Pomalyst (pomalidomide) [prescribing information]. Summit, NJ: Celgene Corporation; June 2016.</p>\n<p>2. Kasserra C, Assaf M, Hoffmann M, et al. Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects. <i>J Clin Pharmacol</i>. 2015;55(2):168-178. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=25159194\">[PubMed 25159194]</a></p>\n<p>3. Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. <i>Clin Pharmacol Ther</i>. 2004;76(6):598-606. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15592331\">[PubMed 15592331]</a></p>\n<p>4. Kim MK, Nightingale C, Nicolau D. Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine. <i>Clin Pharmacokinet</i>. 2003;42(11):985-986. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12908854\">[PubMed 12908854]</a></p>\n<p>5. Nicolau DP, Nightingale CH, Tessier PR, et al. The effect of fleroxacin and ciprofloxacin on the pharmacokinetics of multiple dose caffeine. <i>Drugs</i>. 1995;49(suppl 2):357-359. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8549360\">[PubMed 8549360]</a></p>\n<p>6. Mahr G, Sorgel F, Granneman GR, et al. Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. <i>Clin Pharmacokinet</i>. 1992;22(suppl 1):90-97. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1319876\">[PubMed 1319876]</a></p>\n<p>7. Schwartz J, Jaurequi L, Lettieri J, Bachmann K. Impact of ciprofloxacin on theophylline clearance and steady-state concentrations in serum. <i>Antimicrob Agents Chemother</i>. 1988;32(1):75-77. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3348614\">[PubMed 3348614]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11373":"<p><b>Title</b> Rasagiline / CYP1A2 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Rasagiline. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Limit rasagiline dose to 0.5 mg once daily in patients taking moderate CYP1A2 inhibitors.</p>\n<div>\n <p><b>CYP1A2 Inhibitors (Moderate) Interacting Members</b> Ciprofloxacin (Systemic), Deferasirox, Methoxsalen (Systemic), Mexiletine, Stiripentol, Thiabendazole, Vemurafenib</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study described in the rasagiline prescribing information, the moderate CYP1A2 inhibitor ciprofloxacin (500 mg twice daily) increased the rasagiline (2 mg daily) AUC 83% but had no effect on the rasagiline half-life in 12 healthy volunteers.<sup>1</sup><br><br>Prescribing information recommends limiting the rasagiline dose to 0.5 mg once daily in patients taking CYP1A2 inhibitors.<br><br>Rasagiline is primarily metabolized by CYP1A2.<sup>1</sup> Inhibition of this enzyme by ciprofloxacin may be the likely mechanism responsible for this potential interaction.<sup>2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Azilect (rasagiline) [prescribing information]. North Wales, PA: Teva Pharmaceuticals USA Inc; May 2014.</p>\n<p>2. Cipro (ciprofloxacin) [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc; February 2015.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11374":"<p><b>Title</b> Alosetron / CYP1A2 Inhibitors (Moderate)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> CYP1A2 Inhibitors (Moderate) may increase the serum concentration of Alosetron. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Avoid concomitant use of alosetron and moderate CYP1A2 inhibitors.</p>\n<div>\n <p><b>CYP1A2 Inhibitors (Moderate) Interacting Members</b> Ciprofloxacin (Systemic), Deferasirox, Methoxsalen (Systemic), Mexiletine, Stiripentol, Thiabendazole, Vemurafenib</p>\n</div> \n<p><b>Discussion</b> The AUC of alosetron (1 mg single dose) was increased 6-fold in 40 healthy female subjects when administered on the last day of a 16-day course of the strong CYP1A2 inhibitor fluvoxamine (50 to 200 mg daily in escalating doses).<sup>1</sup> The half-life was increased approximately 3-fold.<sup>1</sup> Moderate inhibitors of CYP1A2 would be expected to have a lesser effect on alosetron exposure, but would be expected to still increase alosetron concentrations significantly (approximately 2- to 5-fold). <br><br>Alosetron prescribing information states that because CYP1A2 inhibitors can increase alosetron concentrations and the risk for adverse effects, the concomitant use of these agents should be avoided.<sup>1</sup> <br><br>The mechanism of this interaction is due to fluvoxamine-mediated inhibition of CYP1A2, an enzyme responsible for alosetron metabolism. Fluvoxamine-mediated inhibition of CYP3A4 or CYP2C9 may also contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Lotronex (alosetron) [prescribing information]. San Diego, CA: Prometheus Laboratories Inc; January 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11375":"<p><b>Title</b> Ramosetron / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> FluvoxaMINE may increase the serum concentration of Ramosetron. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased ramosetron effects/toxicities if combined with fluvoxamine.</p> \n<p><b>Discussion</b> In a pharmacokinetic study described in the ramosetron product label, fluvoxamine (50 mg daily x 1 day, followed by 50 mg twice daily x 9 days) increased the ramosetron (10 mcg single dose) AUC and maximum serum concentration 2.8-fold and 1.4-fold, respectively.<sup>1</sup><br><br>Ramosetron product labeling states that fluvoxamine may increase ramosetron concentrations and patients should be monitored for increased ramosetron toxicities if these agents are combined.<sup>1</sup><br><br>The mechanism of this interaction is likely due to fluvoxamine-mediated inhibition of CYP1A2, an enzyme responsible for ramosetron metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Irribow (ramosetron) tablets [KR prescribing information]. Available at: http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=200905270. Accessed June 17, 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11376":"<p><b>Title</b> Mexiletine / FluvoxaMINE</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> FluvoxaMINE may increase the serum concentration of Mexiletine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased mexiletine effects/toxicities if combined with fluvoxamine.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 6 healthy volunteers, fluvoxamine (50 mg twice daily x 7 days) increased the mexiletine (200 mg single dose) AUC 55% and decreased the mexiletine clearance 38%.<sup>1</sup><br><br>The mechanism of this interaction is likely fluvoxamine-mediated inhibition of CYP1A2, an enzyme responsible for mexiletine metabolism.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Kusumoto M, Ueno K, Oda A, et al. Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men. <i>Clin Pharmacol Ther</i>. 2001;69(3):104-107. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11240973\">[PubMed 11240973]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11377":"<p><b>Title</b> Mirtazapine / Cimetidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Cimetidine may increase the serum concentration of Mirtazapine. <b>Severity</b> Moderate <b>Reliability Rating</b> Good </p> \n<p><b>Patient Management</b> Monitor for increased mirtazapine effects/toxicities if combined with cimetidine. Decreased mirtazapine doses may be required.</p> \n<p><b>Discussion</b> In a pharmacokinetic study of 12 healthy volunteers, cimetidine (800 mg twice daily x 14 days) increased the mirtazapine (30 mg daily x 7 days) AUC and maximum serum concentration 54% and 22%, respectively.<sup>1</sup> Mirtazapine had no effect on the pharmacokinetics of cimetidine.<sup>1</sup><br><br>Mirtazapine prescribing information states that because concomitant use with cimetidine may increase mirtazapine concentrations and risk of adverse effects, patients should be monitored for mirtazapine toxicities if these agents are combined and a reduced mirtazapine dose may be required.<sup>2</sup><br><br>The mechanism of this interaction has not been fully investigated, but cimetidine inhibition of various enzymes involved in mirtazapine metabolism (eg, CYP1A2, CYP2D6, CYP3A4) likely contributes.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Sitsen JM, Maris FA, Timmer CJ. Concomitant use of mirtazapine and cimetidine: a drug-drug interaction study in healthy male subjects. <i>Eur J Clin Pharmacol</i>. 2000;56(5):389-394. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11009047\">[PubMed 11009047]</a></p>\n<p>2. Remeron (mirtazapine) [prescribing information]. Whitehouse Station, NJ: Merck &amp; Co; July 2016.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11378":"<p><b>Title</b> FluvoxaMINE / Mirtazapine</p> \n<p></p> \n<p><b>Risk Rating</b> D: Consider therapy modification</p> \n<p><b>Summary</b> Mirtazapine may enhance the serotonergic effect of FluvoxaMINE. This could result in serotonin syndrome. FluvoxaMINE may increase the serum concentration of Mirtazapine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Consider alternatives to this combination when possible. If combined, monitor for increased mirtazapine effects/toxicities and for signs and symptoms of serotonin syndrome.</p> \n<p><b>Discussion</b> One report describes 2 mirtazapine-treated patients who experienced 3- to 4-fold increases in their mirtazapine serum concentrations after the initiation of fluvoxamine therapy (50 to 100 mg daily).<sup>1</sup> Another report describes a patient treated with fluvoxamine who experienced signs and symptoms of serotonin syndrome (eg, tremors, restlessness, nausea) after the initiation of mirtazapine (30 mg daily).<sup>2</sup><br><br>The mechanism by which fluvoxamine may increase mirtazapine concentrations is likely due to fluvoxamine-mediated inhibition of enzymes involved in mirtazapine metabolism (ie, CYP1A2, CYP3A4, CYP2C9). The mechanism by which this combination may precipitate serotonin syndrome is likely due to additive serotonergic effects.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Anttila AK, Rasanen L, Leinonen EV. Fluvoxamine augmentation increases serum mirtazapine concentrations three- to fourfold. <i>Ann Pharmacother</i>. 2001;35(10):1221-1223. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11675851\">[PubMed 11675851]</a></p>\n<p>2. Demers JC, Malone M. Serotonin syndrome induced by fluvoxamine and mirtazapine. <i>Ann Pharmacother</i>. 2001;35(10):1217-1220. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11675850\">[PubMed 11675850]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11379":"<p><b>Title</b> Agomelatine / Ciprofloxacin (Systemic)</p> \n<p></p> \n<p><b>Risk Rating</b> X: Avoid combination</p> \n<p><b>Summary</b> Ciprofloxacin (Systemic) may increase the serum concentration of Agomelatine. <b>Severity</b> Major <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Concurrent use of agomelatine and ciprofloxacin is contraindicated.</p> \n<p><b>Discussion</b> According to the agomelatine summary of product characteristics, agomelatine exposure was increased approximately 60-fold with concurrent use of the strong CYP1A2 inhibitor fluvoxamine (which is also a moderate inhibitor of CYP2C9, responsible for a minor portion of agomelatine metabolism).<sup>1</sup> As a result, concurrent use of agomelatine with any strong CYP1A2 inhibitor is contraindicated. Although ciprofloxacin is listed as an example of a strong CYP1A2 inhibitor in agomelatine labeling, only one study suggests ciprofloxacin is a strong CYP1A2 inhibitor.<sup>2</sup> Numerous other studies suggest ciprofloxacin is a moderate CYP1A2 inhibitor.<sup>3,4,5,6</sup><br><br>Data suggests CYP1A2 is responsible for approximately 90% of agomelatine metabolism, while CYP2C9 and CYP2C19 account for the remaining 10% of agomelatine metabolism.<sup>1</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Valdoxan (agomelatine) [summary of product characteristics]. Suresnes, France: Les Laboratoires Servier; November 2016.</p>\n<p>2. Granfors MT, Backman JT, Neuvonen M, Neuvonen PJ. Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism. <i>Clin Pharmacol Ther</i>. 2004;76(6):598-606. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15592331\">[PubMed 15592331]</a></p>\n<p>3. Kim MK, Nightingale C, Nicolau D. Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine. <i>Clin Pharmacokinet</i>. 2003;42(11):985-986. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12908854\">[PubMed 12908854]</a></p>\n<p>4. Nicolau DP, Nightingale CH, Tessier PR, et al. The effect of fleroxacin and ciprofloxacin on the pharmacokinetics of multiple dose caffeine. <i>Drugs</i>. 1995;49(suppl 2):357-359. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8549360\">[PubMed 8549360]</a></p>\n<p>5. Mahr G, Sorgel F, Granneman GR, et al. Effects of temafloxacin and ciprofloxacin on the pharmacokinetics of caffeine. <i>Clin Pharmacokinet</i>. 1992;22(suppl 1):90-97. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1319876\">[PubMed 1319876]</a></p>\n<p>6. Schwartz J, Jaurequi L, Lettieri J, Bachmann K. Impact of ciprofloxacin on theophylline clearance and steady-state concentrations in serum. <i>Antimicrob Agents Chemother</i>. 1988;32(1):75-77. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3348614\">[PubMed 3348614]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11380":"<p><b>Title</b> TiZANidine / Amiodarone</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Amiodarone may increase the serum concentration of TiZANidine. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor for increased effects of tizanidine, including adverse reactions (eg, hypotension, bradycardia, drowsiness) if combined with amiodarone. Consider initiating tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response.</p> \n<p><b>Discussion</b> US prescribing information states that tizanidine use in patients taking CYP1A2 inhibitors may increase the risk of adverse reactions (eg, hypotension, bradycardia, excessive drowsiness) and should be avoided if possible.<sup>1</sup> If concomitant use cannot be avoided, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased tizanidine effects/toxicities; if they occur, reduce or discontinue tizanidine therapy.<sup>1</sup> Amiodarone is included as an example of a CYP1A2 inhibitor, and while some in vitro data suggests amiodarone may inhibit CYP1A2,<sup>2,3,4</sup> there are no clinical data in humans showing amiodarone can inhibit CYP1A2.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Zanaflex (tizanidine) [prescribing information]. Ardsley, NY: Acorda Therapeutics Inc; November 2013.</p>\n<p>2. McDonald MG, Au NT, Rettie AE. P450-based drug-drug interactions of amiodarone and its metabolites: diversity of inhibitory mechanisms. <i>Drug Metab Dispos</i>. 2015;43(11):1661-1669. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26296708\">[PubMed 26296708]</a></p>\n<p>3. Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, Yokoi T. Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. <i>Br J Clin Pharmacol</i>. 2000;49(3):244-253. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10718780\">[PubMed 10718780]</a></p>\n<p>4. Kobayashi K, Nakajima M, Chiba K, et al. Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. <i>Br J Clin Pharmacol</i>. 1998;45(4):361-368. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9578183\">[PubMed 9578183]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11381":"<p><b>Title</b> TiZANidine / Famotidine</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Famotidine may increase the serum concentration of TiZANidine. <b>Severity</b> Moderate <b>Reliability Rating</b> Poor </p> \n<p><b>Patient Management</b> Monitor for increased effects of tizanidine, including adverse reactions (eg, hypotension, bradycardia, drowsiness) if combined with famotidine. Consider initiating tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response.</p> \n<p><b>Discussion</b> A single case report describes a patient taking famotidine 40 mg daily who experienced noninfectious cystitis after initiation of tizanidine (2 mg three times daily).<sup>1</sup> Cystitis is a rare side effect associated with tizanidine use and it is unclear if famotidine contributed to the development of this adverse effect or if it was a result of tizanidine alone.<br><br>US prescribing information states that tizanidine use in patients taking CYP1A2 inhibitors may increase the risk of adverse reactions (eg, hypotension, bradycardia, excessive drowsiness) and should be avoided if possible.<sup>2</sup> If concomitant use cannot be avoided, initiate tizanidine at an adult dose of 2 mg and increase in 2 to 4 mg increments based on patient response. Monitor for increased tizanidine effects/toxicities; if they occur, reduce or discontinue tizanidine therapy.<sup>2</sup> Famotidine is included as an example of a CYP1A2 inhibitor, and while one study suggests famotidine may inhibit CYP1A2,<sup>3</sup> the majority of data suggests famotidine has no effect on CYP1A2.<sup>4,5,6,7</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Poudel RR, Kafle NK. Tizanidine-induced acute severe cystitis in a female taking famotidine. <i>Clin Pharmacol</i>. 2015;7:83-85. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=26251632\">[PubMed 26251632]</a></p>\n<p>2. Zanaflex (tizanidine) [prescribing information]. Ardsley, NY: Acorda Therapeutics Inc; November 2013.</p>\n<p>3. Dal Negro R, Pomari C, Turco P. Famotidine and theophylline pharmacokinetics. An unexpected cimetidine-like interaction in patients with chronic obstructive pulmonary disease. <i>Clin Pharmacokinet</i>. 1993;24(3):255-258. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=8462230\">[PubMed 8462230]</a></p>\n<p>4. Bachmannn K, Sullivan TJ, Reese JH, et al. Controlled study of the putative interaction between famotidine and theophylline in patients with chronic obstructive pulmonary disease. <i>J Clin Pharmacol</i>. 1995;35(5):529-535. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7657856\">[PubMed 7657856]</a></p>\n<p>5. Verdiani P, Di Carlo S, Baronti A. Famotidine effects on theophylline pharmacokinetics in subjects affected by COPD. Comparison with cimetidine and placebo. <i>Chest</i>. 1988;94(4):807-810. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=3168576\">[PubMed 3168576]</a></p>\n<p>6. Asamoto H, Kokura M, Kawakami A, et al. Effect of famotidine on theophylline clearance in asthma and COPD patients. <i>Arerugi</i>. 1987;36(11):1012-1017. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2894822\">[PubMed 2894822]</a></p>\n<p>7. Lin JH, Chremos AN, Chiou R, Yeh KC, Williams R. Comparative effect of famotidine and cimetidine on the pharmacokinetics of theophylline in normal volunteers. <i>Br J Clin Pharmacol</i>. 1987;24(5):669-672. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=2893637\">[PubMed 2893637]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11382":"<p><b>Title</b> Theophylline Derivatives / Fluconazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Fluconazole may increase the serum concentration of Theophylline Derivatives. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for increased theophylline concentrations and effects if combined with fluconazole.</p>\n<div>\n <p><b>Theophylline Derivatives Interacting Members</b> Acebrophylline, Aminophylline, Theophylline<br><b>Exception</b> Dyphylline</p>\n</div> \n<p><b>Discussion</b> In a pharmacokinetic study of 16 healthy volunteers described in the fluconazole prescribing information, fluconazole (200 mg daily x 14 days) coadministered with aminophylline (6 mg/kg single intravenous dose) increased the theophylline AUC and maximum serum concentration 21% and 13%, respectively.<sup>1</sup> In contrast, a pharmacokinetic study of 5 healthy volunteers reported that fluconazole (100 mg twice daily x 3 days) had no effect on the pharmacokinetics of theophylline (240 mg single oral dose).<sup>2</sup><br><br>The mechanism of this interaction is unknown, but fluconazole-mediated inhibition of CYP1A2 (the enzyme responsible for theophylline metabolism) appears unlikely, as fluconazole appears to have no effect on CYP1A2 activity.<sup>3,4</sup> Fluconazole-mediated inhibition of CYP3A4, a minor route of theophylline metabolism, may contribute.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Diflucan (fluconazole) [prescribing information]. New York, NY: Pfizer Inc; March 2013.</p>\n<p>2. Konishi H, Morita K, Yamaji A. Effect of fluconazole on theophylline disposition in humans. <i>Eur J Clin Pharmacol</i>. 1994;46(4):309-312. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7957514\">[PubMed 7957514]</a></p>\n<p>3. Niwa T, Inoue-Yamamoto S, Shiraga T, Takagi A. Effect of antifungal drugs on cytochrome P450 (CYP) 1A2, CYP2D6, and CYP2E1 activities in human liver microsomes. <i>Biol Pharm Bull</i>. 2005;28(9):1813-1816. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16141569\">[PubMed 16141569]</a></p>\n<p>4. Maurice M, Pichard L, Daujat M, et al. Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. <i>FASEB J</i>. 1992;6(2):752-758. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=1371482\">[PubMed 1371482]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11383":"<p><b>Title</b> Amphotericin B / Ganciclovir-Valganciclovir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ganciclovir-Valganciclovir may enhance the nephrotoxic effect of Amphotericin B. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for increased serum creatinine or for other evidence of reduced renal function.</p>\n<div>\n <p><b>Amphotericin B Interacting Members</b> Amphotericin B (Conventional), Amphotericin B (Lipid Complex), Amphotericin B (Liposomal), Amphotericin B Cholesteryl Sulfate Complex</p>\n <p><b>Ganciclovir-Valganciclovir Interacting Members</b> Ganciclovir (Systemic), ValGANciclovir</p>\n</div> \n<p><b>Discussion</b> Increases in serum creatinine have been reported with use of ganciclovir, and the labeling for both ganciclovir and valganciclovir recommend caution and increased monitoring of renal function when used with the nephrotoxic agents cyclosporine or amphotericin B.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cytovene-IV (ganciclovir) [prescribing information]. South San Francisco, CA: Genetech USA, Inc.; July 2017.</p>\n<p>2. Valcyte (valganciclovir) [prescribing information]. South San Francisco, CA: Genetech USA, Inc.; June 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11384":"<p><b>Title</b> CycloSPORINE (Systemic) / Ganciclovir-Valganciclovir</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Ganciclovir-Valganciclovir may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <b>Severity</b> Moderate <b>Reliability Rating</b> Fair: Reported in the prescribing information </p> \n<p><b>Patient Management</b> Monitor closely for increased serum creatinine or for other evidence of reduced renal function.</p>\n<div>\n <p><b>Ganciclovir-Valganciclovir Interacting Members</b> Ganciclovir (Systemic), ValGANciclovir</p>\n</div> \n<p><b>Discussion</b> Increases in serum creatinine have been reported with use of ganciclovir, and the labeling for both ganciclovir and valganciclovir recommend caution and increased monitoring of renal function when used with the nephrotoxic agents cyclosporine or amphotericin B.<sup>1,2</sup></p> \n<p><b>Footnotes</b> </p>\n<p>1. Cytovene-IV (ganciclovir) [prescribing information]. South San Francisco, CA: Genetech USA, Inc.; July 2017.</p>\n<p>2. Valcyte (valganciclovir) [prescribing information]. South San Francisco, CA: Genetech USA, Inc.; June 2017.</p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11385":"<p><b>Title</b> Propacetamol / RifAMPin</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> RifAMPin may increase the metabolism of Propacetamol. . This may 1) diminish the desired effects of propacetamol; and 2) increase the risk of liver damage. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Monitor for decreased effects of propacetamol and an elevated risk of hepatotoxicity (due to increased concentrations of acetaminophen metabolites), if rifampin is used concomitantly. This is of particular concern in patients receiving high-dose propacetamol or receiving the combination for a longer duration.</p> \n<p><b>Discussion</b> Labeling for propacetamol states that the risk for hepatotoxicity may be increased with longer-term use of enzyme inducers such as rifampin.<sup>1</sup> Specific data concerning this combination are not available, but several case reports of hepatotoxicity in patients receiving both acetaminophen (a metabolite of proacetamol) and rifampin-containing regimens have been published.<sup>2,3</sup><br><br>Enzyme-inducing agents, including but not limited to rifampin, may increase the clearance of acetaminophen by more than 40%.<sup>4,5,6</sup> <br>This is likely due to induction of CYP isoenzymes and various phase II (ie, conjugating) enzymes, leading to increased acetaminophen metabolism. Acetaminophen-induced hepatotoxicity may be enhanced via enhanced phase I metabolism to a toxic acetaminophen metabolite, exceeding glutathione binding capacity (the mechanism by which the metabolites are cleared).</p> \n<p><b>Footnotes</b> </p>\n<p>1. Denozan (propacetamol) [KR prescribing information]. http://drug.mfds.go.kr/html/bxsSearchDrugProduct.jsp?item_Seq=199500674. Accessed June 5, 2017.</p>\n<p>2. Nolan CM, Sandblom RE, Thummel KE, Slattery JT, Nelson SD. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. <i>Chest</i>. 1994;105(2):408-411. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7508362\">[PubMed 7508362]</a></p>\n<p>3. Stephenson I, Qualie M, Wiselka MJ. Hepatic failure and encephalopathy attributed to an interaction between acetaminophen and rifampicin. <i>Am J Gastroenterol</i>. 2001;96(4):1310-1311. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11316203\">[PubMed 11316203]</a></p>\n<p>4. Perucca E, Richens A. Paracetamol disposition in normal subjects and in patients treated with antiepileptic drugs. <i>Br J Clin Pharmacol</i>. 1979;7(2):201-206. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=760753\">[PubMed 760753]</a></p>\n<p>5. Miners JO, Attwood J, Birkett DJ. Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen's metabolic pathways. <i>Clin Pharmacol Ther</i>. 1984;35(4):480-486. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=6705446\">[PubMed 6705446]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>","11386":"<p><b>Title</b> Citalopram / Esomeprazole</p> \n<p></p> \n<p><b>Risk Rating</b> C: Monitor therapy</p> \n<p><b>Summary</b> Esomeprazole may increase the serum concentration of Citalopram. <b>Severity</b> Moderate <b>Reliability Rating</b> Fair </p> \n<p><b>Patient Management</b> Limit citalopram dose to a maximum of 20 mg/day if used with esomeprazole. Patients using this combination should be monitored closely for evidence of citalopram toxicity (eg, serotonin syndrome, QT prolongation, etc.).</p> \n<p><b>Discussion</b> Citalopram concentration/dose ratios were an average of 32.8% higher with concurrent esomeprazole according to data from an analysis of 275 samples from 202 patients who were being treated with both citalopram and a selective serotonin reuptake inhibitor (103 were specifically with esomeprazole).<sup>1</sup><br><br>The citalopram prescribing information states that the citalopram dose should be limited to a maximum of 20 mg/day in patients who are receiving a CYP2C19 inhibitor due to the likelihood for increased citalopram concentrations and the possible increased risk for toxicities such as QT prolongation, and the labeling specifically lists omeprazole as an example of a potent CYP2C19 inhibitor.<sup>2</sup> Although esomeprazole is not specifically listed, similarities between esomeprazole and omeprazole suggest a similar interaction potential would apply to esomeprazole as does to omeprazole.<br><br>Average concentrations of (+)-(S)-citalopram were approximately 2.2-fold higher with concurrent use of omeprazole (20 mg/day for 18 days), in two small separate studies of healthy volunteers (n=9-12).<sup>3</sup> A study of the single enantiomer product escitalopram also reported a 1.5-fold average increase in escitalopram concentrations with concurrent use of omeprazole (30 mg/day for 6 days).<sup>4</sup><br><br>The mechanism for this interaction is most likely inhibition of citalopram metabolism via CYP2C19, leading to increased citalopram concentrations. Although the citalopram label lists omeprazole as a potent CYP2C19 inhibitor, data with several CYP2C19 substrates suggests both esomeprazole and omeprazole are more likely only weak CYP2C19 inhibitors.</p> \n<p><b>Footnotes</b> </p>\n<p>1. Gjestad C, Westin AA, Skogvoll E, Spigset O. Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline. <i>Ther Drug Monit</i>. 2015;37(1):90-97. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=24887634\">[PubMed 24887634]</a></p>\n<p>2. Celexa (citalopram) [prescribing information]. Irvine, CA: Allergan USA, Inc.; January 2017.</p>\n<p>3. Rocha A, Coelho EB, Sampaio SA, et al. Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers. <i>Br J Clin Pharmacol</i>. 2010;70(1):43-51. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20642546\">[PubMed 20642546]</a></p>\n<p>4. Malling D, Poulsen MN, Sogaard B. The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects. <i>Br J Clin Pharmacol</i>. 2005;60(3):287-290. <a target=\"_blank\" href=\"https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16120067\">[PubMed 16120067]</a></p>\n<p></p> \n<hr> \n<span style=\"color: black; font-size: 80%; font-style: italic\">Â© 2018 Wolters Kluwer Clinical Drug Information, Inc. and its affiliates and/or licensors. All rights reserved.</span>"}